

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

29 October 2020 (29.10.2020)



(10) International Publication Number

WO 2020/219906 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 45/06 (2006.01)

A61K 31/519 (2006.01) A61P 35/00 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(21) International Application Number:

PCT/US2020/029851

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

24 April 2020 (24.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/838,702 25 April 2019 (25.04.2019) US

(71) Applicant: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th Street, Austin, TX 78701 (US).

(72) Inventors: **HEYMACH, John**; 2036 Southgate Boulevard, Houston, TX 77030 (US). **ROBICHAUX, Jacquelyne**; 3310 Ewing Drive, Manvel, TX 77578 (US). **NILSSON, Monique**; 3319 Richland Drive, Sugar Land, TX 77478 (US). **JONES, Philip**; 2727 Carolina Way, Houston, TX 77005 (US). **CROSS, Jason**; 2821 Moss Lake Lane, Pearland, TX 77584 (US). **THEROFF, Jay**; 2707 Driftwood Drive, Manvel, TX 77578 (US).

(74) Agent: **BENNETT, Dennis**; Global Patent Group, LLC, c/o Missouri Patent Services LLC, 2275 Cassens Drive, Suite 118, St. Louis, MO 63026 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: HETEROCYCLIC INHIBITORS OF TYROSINE KINASE

(57) Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.

WO 2020/219906 A1

TITLE: HETEROCYCLIC INHIBITORS OF TYROSINE KINASE

[001] This application claims the benefit of priority of United States Provisional Application No. 62/838,702, filed Apr 25, 2019, the disclosure of which is hereby incorporated by reference as if written herein in its entirety.

[002] Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of tyrosine kinase activity in a human or animal subject are also provided for the treatment diseases such as cancer.

[003] Tyrosine kinases promote the phosphorylation of the phenolic hydroxyl of tyrosine, and this activity is commonly used to modulate the functionality of proteins. Mutations in tyrosine kinases are suspected in causing unregulated cell growth, leading to cancer. For this reason, tyrosine kinase inhibitors (TKIs) have been developed for their anticancer activity.

[004] The ErbB family of proteins (named for the homologous erythroblastic leukemia viral oncogene) contains four tyrosine kinases, structurally related to the human epidermal growth factor receptor (EGFR, also termed Her1 or ErbB1), discovered by Stanley Cohen. Abnormalities in EGFR have been identified as causative for cancer. The ErbB family also includes HER2 (Neu or ErbB2), HER3 (ErbB3) and HER4 (ErbB4).

[005] ErbB receptors are overexpressed or mutated in many cancers, including cancers of the stomach, colon, rectum, head and neck, breast, ovary, pancreas, lung (NSCLC) and brain (glioblastoma). The overexpression and overactivation of ErbB receptors are correlated with poor prognosis, drug resistance, cancer metastasis, and lower survival rate. For this reason, ErbB receptors, especially EGFR and HER2 have been targeted for cancer chemotherapy.

[006] The presence of mutations in an ErbB protein can influence the likelihood of successful treatment for certain cancers. Afatinib (GILOTRIF®), a TKI indicated for the treatment of certain NSCLC patients, inhibits WT EGFR and HER2 but does not effectively inhibit exon 20 mutant EGFR or HER2. Similarly, trastuzumab (HERCEPTIN®) is ineffective by itself against HER2 exon 20 insertions.

[007] Beyond NSCLC, EGFR and HER2 exon 20 insertions are also observed in gastric cancer, breast cancer, glioblastomas, adenoid cystic carcinoma, and a number of


gastrointestinal ailments. In fact, the number of non-lung cancer exon 20 mutations is larger than the number of lung cancer exon 20 mutations.

[008] NSCLC patients harboring in-frame mutations (usually insertions) with exon 20 are resistant to FDA-approved EGFR TKIs, with an objective response rate of approximately 4-8% and a median progression-free survival (PFS) of < 2 months, based on retrospective studies. Studies have shown that exon 20 insertions have a stabilized active conformation of EGFR, and lack affinity to currently available EGFR TKI. Other studies have reported that HER2 exon 20 mutations have heterogeneous responses to TKIs, but have not established an effective inhibitor of HER2 mutations. Furthermore, many patients experience dose limiting toxicities on currently available EGFR and HER2 targeted agents such as afatinib, dacomitinb, and neratinib due to off-target inhibition of wild-type (WT) EGFR. Additional agents with selective activity against exon 20 mutant EGFR and HER2 but not WT EGFR are required to reduce toxicity of targeted agents and improve clinical outcomes. Thus there is an unmet need to develop and identify inhibitors that target both EGFR and HER2 exon 20 mutations, as well as other EGFR and HER2 activating mutations.

[009] Novel compounds and pharmaceutical compositions, certain of which have been found to inhibit mutant HER2 have been discovered, together with methods of synthesizing and using the compounds including methods for the treatment of HER2-mediated diseases in a patient by administering the compounds.

DETAILED DESCRIPTION

[010] Provided herein is **Embodiment 1**: a compound having structural Formula (I):



or a salt thereof, wherein:

A¹ is chosen from C(R¹) and N;

A² is chosen from C(R²) and N;

A³ is chosen from C(R³) and N;

Ar¹ is chosen from aryl and heteroaryl, either of which is optionally substituted with one or two R⁴ groups, and either of which is optionally substituted with one, two, or three R⁵ groups;

R¹ is chosen from halo, -CN, -OR⁶, -NR^{7a}R^{7b}, -COOR⁸, and -CONR^{9a}R^{9b};

R² and R³ are independently chosen from H, alkyl, and alkoxy;

each R⁴ is independently chosen from alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which is optionally substituted with one or two R¹⁰ groups;

each R⁵ is independently chosen from halo, -CN, -OR¹¹, -NR^{12a}R^{12b}, -COOR¹³, and -CONR^{14a}R^{14b};

each R⁶, R^{7a}, and R^{7b} is independently chosen from H, alkyl, haloalkyl, and C(=O)alkyl;

each R⁸, R^{9a}, and R^{9b} is independently chosen from H and alkyl;

each R¹⁰ is independently chosen from halo, hydroxy, and alkoxy;

each R¹¹, R^{12a}, and R^{12b} is independently chosen from H, C₁₋₆alkyl, C₁₋₆haloalkyl, and C(=O)C₁₋₆alkyl; and

each R¹³, R^{14a}, and R^{14b} is independently chosen from H and C₁₋₆alkyl.

[011] Certain compounds disclosed herein may possess useful HER2 inhibiting activity, and may be used in the treatment or prophylaxis of a disease or condition in which HER2 plays an active role. Thus, in broad aspect, certain embodiments also provide pharmaceutical compositions comprising one or more compounds disclosed herein together with a pharmaceutically acceptable carrier, as well as methods of making and using the compounds and compositions. Certain embodiments provide methods for inhibiting HER2. Certain embodiments provide selectivity for the inhibition of certain mutant forms of HER2 over wild type (WT) EGFR. Other embodiments provide methods for treating a HER2-mediated disorder in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a compound or composition according to the present disclosure. Also provided is the use of certain compounds disclosed herein for use in the manufacture of a medicament for the treatment of a disease or condition ameliorated by the inhibition of HER2.

[012] Certain compounds disclosed herein may possess useful EGFR inhibiting activity, and may be used in the treatment or prophylaxis of a disease or condition in which EGFR plays an active role. Thus, in broad aspect, certain embodiments also provide pharmaceutical compositions comprising one or more compounds disclosed herein together with a

pharmaceutically acceptable carrier, as well as methods of making and using the compounds and compositions. Certain embodiments provide methods for inhibiting EGFR. Certain embodiments provide selectivity for the inhibition of certain mutant forms of EGFR over wild type (WT) EGFR. Other embodiments provide methods for treating an EGFR-mediated disorder in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a compound or composition according to the present disclosure. Also provided is the use of certain compounds disclosed herein for use in the manufacture of a medicament for the treatment of a disease or condition ameliorated by the inhibition of EGFR.

[013] Also provided are the following embodiments:

[014] **Embodiment 2:** The compound of Embodiment 1, wherein A^1 is $C(R^1)$.

[015] **Embodiment 3:** The compound of Embodiment 2, wherein R^1 is -CN.

[016] **Embodiment 4:** The compound of Embodiment 2, wherein R^1 is chosen from $-OR^6$ and $-NR^{7a}R^{7b}$.

[017] **Embodiment 5:** The compound of Embodiment 4, wherein each R^6 , R^{7a} , and R^{7b} is H.

[018] **Embodiment 6:** The compound of Embodiment 4, wherein each R^6 , R^{7a} , and R^{7b} is alkyl.

[019] **Embodiment 7:** The compound of Embodiment 4, wherein each R^6 , R^{7a} , and R^{7b} is $C(=O)alkyl$.

[020] **Embodiment 8:** The compound of any one of Embodiments 4 – 7, wherein R^1 is $-OR^6$.

[021] **Embodiment 9:** The compound of any one of Embodiments 4 – 7, wherein R^1 is $-NR^{7a}R^{7b}$.

[022] **Embodiment 10:** The compound of Embodiment 2, wherein R^1 is chosen from $-COOR^8$ and $-CONR^{9a}R^{9b}$.

[023] **Embodiment 11:** The compound of Embodiment 10, wherein each R^8 , R^{9a} , and R^{9b} is H.

[024] **Embodiment 12:** The compound of Embodiment 10, wherein each R^8 , R^{9a} , and R^{9b} is alkyl.

[025] **Embodiment 13:** The compound of any one of Embodiments 10 – 12, wherein R^1 is $-COOR^8$.

[026] **Embodiment 14:** The compound of any one of Embodiments **10 – 12**, wherein R^1 is $-\text{CONR}^{9a}\text{R}^{9b}$.

[027] **Embodiment 15:** The compound of Embodiment **1**, wherein A^1 is N.

[028] **Embodiment 16:** The compound of any one of Embodiments **1 – 15**, wherein A^2 is $\text{C}(\text{R}^2)$.

[029] **Embodiment 17:** The compound of Embodiment **16**, wherein R^2 is alkyl.

[030] **Embodiment 18:** The compound of Embodiment **16**, wherein R^2 is alkoxy.

[031] **Embodiment 19:** The compound of Embodiment **16**, wherein R^2 is H.

[032] **Embodiment 20:** The compound of any one of Embodiments **1 – 15**, wherein A^2 is N.


[033] **Embodiment 21:** The compound of any one of Embodiments **1 – 20**, wherein A^3 is $\text{C}(\text{R}^3)$.

[034] **Embodiment 22:** The compound of Embodiment **21**, wherein R^3 is alkyl.

[035] **Embodiment 23:** The compound of Embodiment **21**, wherein R^3 is H.

[036] **Embodiment 24:** The compound of any one of Embodiments **1 – 20**, wherein A^3 is N.

[037] Also provided is **Embodiment 25:** a compound having structural Formula (II):



or a salt thereof, wherein:

Ar^1 is chosen from aryl and heteroaryl, either of which is optionally substituted with one or two R^4 groups, and either of which is optionally substituted with one, two, or three R^5 groups;

each R^4 is independently chosen from alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which is optionally substituted with one or two R^{10} groups;

each R^5 is independently chosen from halo, $-\text{CN}$, $-\text{OR}^{11}$, $-\text{NR}^{12a}\text{R}^{12b}$, $-\text{COOR}^{13}$, and $-\text{CONR}^{14a}\text{R}^{14b}$;

each R^{10} is independently chosen from halo, hydroxy, and alkoxy;

each R^{11} , R^{12a} , and R^{12b} is independently chosen from H, C_{1-6} alkyl, C_{1-6} haloalkyl, and $\text{C}(=\text{O})\text{C}_{1-6}$ alkyl;

each R^{13} , R^{14a} , and R^{14b} is independently chosen from H and C_{1-6} alkyl; and Y^1 is chosen from -NH- and -O-.

[038] Also provided are the following embodiments:

[039] **Embodiment 26:** The compound of any one of Embodiments **1 – 25**, wherein Ar^1 is chosen from phenyl and monocyclic heteroaryl, either of which is optionally substituted with one or two R^4 groups, and either of which is substituted with one, two, or three R^5 groups.

[040] **Embodiment 27:** The compound of Embodiment **26**, wherein Ar^1 is chosen from phenyl and monocyclic 6-membered heteroaryl, either of which is optionally substituted with one or two R^4 groups, and either of which is substituted with one, two, or three R^5 groups.

[041] **Embodiment 28:** The compound of Embodiment **27**, wherein Ar^1 is chosen from phenyl, pyridyl, pyrimidyl, pyridazyl, and pyrazyl, any of which is optionally substituted with one or two R^4 groups, and any of which is substituted with one, two, or three R^5 groups.

[042] **Embodiment 29:** The compound of Embodiment **28**, wherein Ar^1 is phenyl, and is optionally substituted with one or two R^4 groups, and is substituted with one, two, or three R^5 groups.

[043] **Embodiment 30:** The compound of Embodiment **28**, wherein Ar^1 is chosen from pyridyl, pyrimidyl, pyridazyl, and pyrazyl, any of which is optionally substituted with one or two R^4 groups, and any of which is substituted with one, two, or three R^5 groups.

[044] **Embodiment 31:** The compound of Embodiment **30**, wherein Ar^1 is pyridyl, and is optionally substituted with one or two R^4 groups, and is substituted with one, two, or three R^5 groups.

[045] **Embodiment 32:** The compound of Embodiment **30**, wherein Ar^1 is chosen from pyrimidyl, pyridazyl, and pyrazyl, any of which is optionally substituted with one or two R^4 groups, and any of which is substituted with one, two, or three R^5 groups.

[046] **Embodiment 33:** The compound of any one of Embodiments **1 – 25**, wherein Ar^1 is chosen from naphthyl and bicyclic heteroaryl, either of which is optionally substituted with one or two R^4 groups, and either of which is substituted with one, two, or three R^5 groups.

[047] **Embodiment 34:** The compound of Embodiment **33**, wherein Ar^1 is bicyclic heteroaryl, and is optionally substituted with one or two R^4 groups, and is substituted with one, two, or three R^5 groups.

[048] **Embodiment 35:** The compound of Embodiment **34**, wherein Ar¹ is bicyclic 10-membered heteroaryl, and is optionally substituted with one or two R⁴ groups, and is substituted with one, two, or three R⁵ groups.

[049] **Embodiment 36:** The compound of Embodiment **35**, wherein Ar¹ is chosen from quinolinyl and isoquinolinyl, either of which is optionally substituted with one or two R⁴ groups, and either of which is substituted with one, two, or three R⁵ groups.

[050] **Embodiment 37:** The compound of Embodiment **34**, wherein Ar¹ is bicyclic 9-membered heteroaryl, and is optionally substituted with one or two R⁴ groups, and is substituted with one, two, or three R⁵ groups.

[051] **Embodiment 38:** The compound of Embodiment **37**, wherein Ar¹ is chosen from indolyl, benzimidazolyl, benzopyrrolyl, benzoxazolyl, and benzisoxazolyl, any of which is optionally substituted with one or two R⁴ groups, and any of which is substituted with one, two, or three R⁵ groups.

[052] **Embodiment 39:** The compound of Embodiment **38**, wherein Ar¹ is chosen from indolyl, benzimidazolyl, and benzopyrrolyl, any of which is optionally substituted with one or two R⁴ groups, and any of which is substituted with one, two, or three R⁵ groups.

[053] **Embodiment 40:** The compound of any one of Embodiments **1 – 39**, wherein Ar¹ is optionally substituted with one R⁴ group.

[054] **Embodiment 41:** The compound of any one of Embodiments **1 – 39**, wherein Ar¹ is substituted with one or two R⁴ groups.

[055] **Embodiment 42:** The compound of Embodiment **41**, wherein Ar¹ is substituted with one R⁴ group.

[056] **Embodiment 43:** The compound of Embodiment **41**, wherein Ar¹ is substituted with two R⁴ groups.

[057] **Embodiment 44:** The compound of any one of Embodiments **1 – 43**, wherein each R⁴ is independently chosen from C₁₋₆alkyl, C₃₋₇cycloalkyl, 4- to 7-membered heterocycloalkyl, C₆₋₁₀aryl, and 6- to 10-membered heteroaryl, any of which is optionally substituted with one or two R¹⁰ groups.

[058] **Embodiment 45:** The compound of Embodiment **44**, wherein each R⁴ is C₃₋₇cycloalkyl, and is optionally substituted with one or two R¹⁰ groups.


[059] **Embodiment 46:** The compound of Embodiment **44**, wherein each R⁴ is C₁₋₆alkyl, and is optionally substituted with one or two R¹⁰ groups.

[060] **Embodiment 47:** The compound of Embodiment **44**, wherein each R⁴ is C₁₋₆alkyl, and is optionally substituted with one or two R¹⁰ groups.


- [061] **Embodiment 48:** The compound of Embodiment **44**, wherein each R^4 is independently chosen from C_{3-7} cycloalkyl and 4- to 7-membered heterocycloalkyl, either of which is optionally substituted with one or two R^{10} groups.
- [062] **Embodiment 49:** The compound of Embodiment **44**, wherein each R^4 is independently chosen from C_{6-10} aryl and 6- to 10-membered heteroaryl, either of which is optionally substituted with one or two R^{10} groups.
- [063] **Embodiment 50:** The compound of Embodiment **49**, wherein each R^4 is 6- to 10-membered heteroaryl and is optionally substituted with one or two R^{10} groups.
- [064] **Embodiment 51:** The compound of Embodiment **50**, wherein each R^4 is monocyclic 5- to 7-membered heteroaryl and is optionally substituted with one or two R^{10} groups.
- [065] **Embodiment 52:** The compound of Embodiment **51**, wherein each R^4 is chosen from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, and isoxazolyl, and is optionally substituted with one or two R^{10} groups.
- [066] **Embodiment 53:** The compound of Embodiment **52**, wherein each R^4 is oxazolyl and is optionally substituted with one or two R^{10} groups.
- [067] **Embodiment 54:** The compound of any one of Embodiments **1 – 53**, wherein each R^4 is optionally substituted with one R^{10} group.
- [068] **Embodiment 55:** The compound of any one of Embodiments **1 – 53**, wherein each R^4 is substituted with one or two R^{10} groups.
- [069] **Embodiment 56:** The compound of Embodiment **55**, wherein each R^4 is substituted with one R^{10} group.
- [070] **Embodiment 57:** The compound of any one of Embodiments **1 – 56**, wherein R^{10} is halo.
- [071] **Embodiment 58:** The compound of any one of Embodiments **1 – 56**, wherein R^{10} is hydroxy.
- [072] **Embodiment 59:** The compound of any one of Embodiments **1 – 56**, wherein R^{10} is alkoxy.
- [073] **Embodiment 60:** The compound of Embodiment **59**, wherein R^{10} is C_{1-6} alkoxy.
- [074] **Embodiment 61:** The compound of Embodiment **54**, wherein each R^4 is not substituted with an R^{10} group.
- [075] **Embodiment 62:** The compound of Embodiment **45**, wherein each R^4 is cyclopropyl.

- [076] **Embodiment 63:** The compound of Embodiment **45**, wherein each R⁴ is cyclobutyl.
- [077] **Embodiment 64:** The compound of Embodiment **46**, wherein each R⁴ is C₁₋₆alkyl.
- [078] **Embodiment 65:** The compound of Embodiment **64**, wherein each R⁴ is methyl.
- [079] **Embodiment 66:** The compound of Embodiment **46**, wherein each R⁴ is hydroxyalkyl.
- [080] **Embodiment 67:** The compound of Embodiment **66**, wherein each R⁴ is hydroxymethyl.
- [081] **Embodiment 68:** The compound of Embodiment **40**, wherein Ar¹ is not substituted with an R⁴ group.
- [082] **Embodiment 69:** The compound of any one of Embodiments **1 – 68**, wherein Ar¹ is optionally substituted with one or two R⁵ groups.
- [083] **Embodiment 70:** The compound of Embodiment **69**, wherein Ar¹ is optionally substituted with one R⁵ group.
- [084] **Embodiment 71:** The compound of any one of Embodiments **1 – 68**, wherein Ar¹ is substituted with one, two, or three R⁵ groups.
- [085] **Embodiment 72:** The compound of Embodiment **71**, wherein Ar¹ is substituted with one or two R⁵ groups.
- [086] **Embodiment 73:** The compound of Embodiment **72**, wherein Ar¹ is substituted with one R⁵ group.
- [087] **Embodiment 74:** The compound of any one of Embodiments **1 – 73**, wherein each R⁵ is independently chosen from halo and cyano.
- [088] **Embodiment 75:** The compound of any one of Embodiments **1 – 73**, wherein each R⁵ is independently chosen from -OR¹¹ and -NR^{12a}R^{12b}.
- [089] **Embodiment 76:** The compound of Embodiment **75**, wherein each R¹¹, R^{12a}, and R^{12b} is H.
- [090] **Embodiment 77:** The compound of Embodiment **75**, wherein each R⁵ is -OR¹¹.
- [091] **Embodiment 78:** The compound of Embodiment **77**, wherein each R¹¹ is alkyl.
- [092] **Embodiment 79:** The compound of Embodiment **75**, wherein each R¹¹ is C₁₋₆alkyl.
- [093] **Embodiment 80:** The compound of Embodiment **75**, wherein each R¹¹ is C₁₋₆haloalkyl.

- [094] **Embodiment 81:** The compound of Embodiment **80**, wherein each R^{11} is halomethyl.
- [095] **Embodiment 82:** The compound of Embodiment **81**, wherein each R^{11} is difluoromethyl.
- [096] **Embodiment 83:** The compound of Embodiment **81**, wherein each R^{11} is trifluoromethyl.
- [097] **Embodiment 84:** The compound of Embodiment **75**, wherein each R^{11} , R^{12a} , and R^{12b} is $C(=O)$ alkyl.
- [098] **Embodiment 85:** The compound of Embodiment **84**, wherein each R^{11} , R^{12a} , and R^{12b} is $C(=O)C_{1-6}$ alkyl.
- [099] **Embodiment 86:** The compound of any one of Embodiments **1 – 73**, wherein each R^5 is independently chosen from $-COOR^{13}$, and $-CONR^{14a}R^{14b}$.
- [0100] **Embodiment 87:** The compound of Embodiment **86**, wherein each R^{13} , R^{14a} , and R^{14b} is H.
- [0101] **Embodiment 88:** The compound of Embodiment **86**, wherein each R^{13} , R^{14a} , and R^{14b} is alkyl.
- [0102] **Embodiment 89:** The compound of Embodiment **88**, wherein each R^{13} , R^{14a} , and R^{14b} is C_{1-6} alkyl.
- [0103] **Embodiment 90:** The compound of any one of Embodiments **86 – 89**, wherein R^5 is $-COOR^{13}$.
- [0104] **Embodiment 91:** The compound of any one of Embodiments **86 – 89**, wherein R^5 is $-CONR^{14a}R^{14b}$.
- [0105] **Embodiment 92:** The compound of Embodiment **70**, wherein Ar^1 is not substituted with an R^5 group.
- [0106] **Embodiment 93:** The compound of Embodiment **29**, wherein Ar^1 is chosen from:




[0107] **Embodiment 94:** The compound of Embodiment 93, wherein Ar¹ is chosen from



[0108] Also provided are embodiments wherein any embodiment above may be combined with any one or more of these embodiments, provided the combination is not mutually exclusive.

[0109] As used herein, two embodiments are “mutually exclusive” when one is defined to be something which is different than the other. For example, an embodiment wherein two groups combine to form a cycloalkyl is mutually exclusive with an embodiment in which one group is ethyl the other group is hydrogen. Similarly, an embodiment wherein one group is CH₂ is mutually exclusive with an embodiment wherein the same group is NH.

[0110] Also provided is a compound chosen from:



[0111] In one aspect, the present disclosure provides methods of inhibiting at least one HER2 function comprising the step of contacting HER2 with a compound as described herein. The cell phenotype, cell proliferation, activity of HER2, change in biochemical output produced by active HER2, expression of HER2, or binding of HER2 with a natural binding partner may be monitored. Such methods may be modes of treatment of disease, biological assays, cellular assays, biochemical assays, or the like.

[0112] Also provided herein is a method of treatment of a HER2-mediated disease comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a salt thereof, to a patient in need thereof.

[0113] In certain embodiments, the HER2-mediated disease is cancer.

[0114] Also provided herein is a compound as disclosed herein for use as a medicament.

[0115] Also provided herein is a compound as disclosed herein for use as a medicament for the treatment of a HER2-mediated disease.

[0116] Also provided is the use of a compound as disclosed herein as a medicament.

[0117] Also provided is the use of a compound as disclosed herein as a medicament for the treatment of a HER2-mediated disease.

[0118] Also provided is a compound as disclosed herein for use in the manufacture of a medicament for the treatment of a HER2-mediated disease.

[0119] Also provided is the use of a compound as disclosed herein for the treatment of a HER2-mediated disease.

[0120] Also provided herein is a method of inhibition of HER2 comprising contacting HER2 with a compound as disclosed herein, or a salt thereof.

[0121] Compounds of the present disclosure may be selective for a mutant form of HER2 over WT EGFR in various ways. In one aspect, compounds described herein may be selective for a mutant form of HER2 over WT EGFR, wherein HER2 comprises an exon 20 insertion mutation (defined as insertions of 1-18 amino acids between amino acids E770-R786 in HER2). In another aspect, compounds described herein may be selective for a mutant form of HER2 over WT EGFR, wherein HER2 comprises a point mutation in exon 20 excluding C805S in HER2. In yet another aspect, compounds described herein may be selective for a mutant form of HER2 over WT EGFR, wherein HER2 comprises an activating mutation, including but not limited to an extracellular mutation, an exon 19 point mutation such as a mutation at L755 or D769, and an exon 21 point mutation such as a mutation at V842I or L869R. In yet another aspect, compounds described herein may be selective for a mutant form of HER2 over WT EGFR, wherein the mutant form of HER2 is chosen from YVMA, GSP, VC, V754M, L755S, L755P, D769H, D769N, Y772dupYVMA, V773M, G776delinsVC, G776delinsVV, G776delinsLC, G778insLPS, G778dupGSP, V777L, G778insLPS, G778dupGSP, L786V, V842I, and L869R.

[0122] Certain compounds may display selectivity for a mutant HER2, quantified as the ratio $IC_{50}(\text{mutant HER2}) / IC_{50}(\text{wt EGFR})$ of 0.5 or less. Certain compounds may display selectivity for a mutant HER2 of 0.2 or less. Certain compounds may display selectivity for a mutant HER2 of 0.05 or less. Certain compounds may display selectivity for a mutant HER2 of 0.02 or less.

[0123] Also provided is a method of modulation of a HER2-mediated function in a subject comprising the administration of a therapeutically effective amount of a compound as disclosed herein.

[0124] Also provided is a method of treating a subject having a HER2-mediated disease or disorder, such as a cancer or tumor. The method comprises determining that the genotype

of the subject comprises a mutant form of HER2, and administering a compound as disclosed herein, or a salt thereof, to the subject.

[0125] Also provided is a method for treating a HER2-mediated disease or disorder, such as a cancer or tumor, in a subpopulation of subjects, the subpopulation being characterized by the presence of a mutant form of HER2 in the genotype of the subjects of the subpopulation, and administering a compound as disclosed herein, or a salt thereof, to the subjects in the subpopulation.

[0126] Also provided is a method for stratifying a subject for response to therapy comprising administration of a compound as disclosed herein, or a salt thereof, the method comprising the steps of determining the presence of a mutant form of HER2 in the genotype of the subject, and administering a compound as disclosed herein, or a salt thereof.

[0127] In one aspect, the present disclosure provides methods of inhibiting at least one EGFR function comprising the step of contacting EGFR with a compound as described herein. The cell phenotype, cell proliferation, activity of EGFR, change in biochemical output produced by active EGFR, expression of EGFR, or binding of EGFR with a natural binding partner may be monitored. Such methods may be modes of treatment of disease, biological assays, cellular assays, biochemical assays, or the like.

[0128] Also provided herein is a method of treatment of an EGFR-mediated disease comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a salt thereof, to a patient in need thereof.

[0129] In certain embodiments, the EGFR-mediated disease is cancer.

[0130] Also provided herein is a compound as disclosed herein for use as a medicament.

[0131] Also provided herein is a compound as disclosed herein for use as a medicament for the treatment of an EGFR-mediated disease.

[0132] Also provided is the use of a compound as disclosed herein as a medicament.

[0133] Also provided is the use of a compound as disclosed herein as a medicament for the treatment of an EGFR-mediated disease.

[0134] Also provided is a compound as disclosed herein for use in the manufacture of a medicament for the treatment of an EGFR-mediated disease.

[0135] Also provided is the use of a compound as disclosed herein for the treatment of a HER2-mediated disease.

[0136] Also provided herein is a method of inhibition of EGFR comprising contacting EGFR with a compound as disclosed herein, or a salt thereof.

[0137] Compounds of the present disclosure may be selective for a mutant form of EGFR over WT EGFR in various ways. In one aspect, compounds described herein may be selective for a mutant form of EGFR over WT EGFR, wherein the EGFR comprises an exon 20 insertion mutation (defined as insertions of 1-18 amino acids between amino acids A763-R776 in EGFR). In another aspect, compounds described herein may be selective for a mutant form of EGFR over WT EGFR, wherein EGFR comprises a point mutation in exon 20 excluding C797S in EGFR. In another aspect, compounds described herein may be selective for a mutant form of EGFR over WT EGFR, wherein EGFR comprises an atypical mutation, including but not limited to L719, G724, and L792. In yet another aspect, compounds described herein may be selective for a mutant form of EGFR over WT EGFR, wherein the mutant form of EGFR is chosen from S768I, S768dupSVD, D770insNPG, D770insSVD, V774insHV, A763insFQEA, A767insASV, S768I T790M, V769L, A767insTLA, V769insMASVD, V769insGSV, V769insGVV, V769insASV, D770del insGY, D770insY H773Y, D770insG, N771insSVDNR, N771insHH, P772insDNP, A763insFQEA, A767insASV, A767insTLA, S768I, S768dupSVD, V769L, V769insASV, V769insGSV, V769insGVV, V769insMASVD, D770del insGY, D770insY H773Y, D770insNPG, D770insG, D770insSVD, N771insSVDNR, N771insHH, P772insDNP, H773insAH, H773insNPH, H773insH, H773L V774M, V774insHVVH773insAH H773L / V774M, D770insNPG / C797S, D770insNPG / T790M, S768dupSVD / C797S, S768dupSVD / T790M, and H773insNPH.

[0138] Certain compounds may display selectivity for a mutant EGFR, quantified as the ratio $IC_{50}(\text{mutant EGFR}) / IC_{50}(\text{wt EGFR})$ of 0.5 or less. Certain compounds may display selectivity for a mutant EGFR of 0.2 or less. Certain compounds may display selectivity for a mutant EGFR of 0.05 or less. Certain compounds may display selectivity for a mutant EGFR of 0.02 or less.

[0139] Also provided is a method of modulation of an EGFR-mediated function in a subject comprising the administration of a therapeutically effective amount of a compound as disclosed herein.

[0140] Also provided is a method of treating a subject having an EGFR-mediated disease or disorder, such as a cancer or tumor. The method comprises determining that the genotype of the subject comprises a mutant form of EGFR, and administering a compound as disclosed herein, or a salt thereof, to the subject.

[0141] Also provided is a method for treating an EGFR-mediated disease or disorder, such as a cancer or tumor, in a subpopulation of subjects, the subpopulation being characterized by the presence of a mutant form of EGFR in the genotype of the subjects of the subpopulation, and administering a compound as disclosed herein, or a salt thereof, to the subjects in the subpopulation.

[0142] Also provided is a method for stratifying a subject for response to therapy comprising administration of a compound as disclosed herein, or a salt thereof, the method comprising the steps of determining the presence of a mutant form of EGFR in the genotype of the subject, and administering a compound as disclosed herein, or a salt thereof.

[0143] Thus, in another aspect, certain embodiments provide methods for treating disorders mediated by HER2 or EGFR in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound disclosed herein effective to reduce or prevent said disorder in the subject.

[0144] In certain embodiments, the disorder is a cancer. The cancer may be any cancer now known, or later discovered, including, but not limited to, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Adrenocortical Carcinoma, AIDS-Related Cancers (Kaposi Sarcoma and Lymphoma), Anal Cancer, Appendix Cancer, Atypical Teratoid/Rhabdoid Tumor, Basal Cell Carcinoma, Bile Duct Cancer (including Extrahepatic), Bladder Cancer, Bone Cancer (including Osteosarcoma and Malignant Fibrous Histiocytoma), Brain Tumor (such as Astrocytomas, Brain and Spinal Cord Tumors, Brain Stem Glioma, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Tumors, Craniopharyngioma, Ependymoblastoma, Ependymoma, Medulloblastoma, Medulloepithelioma, Pineal Parenchymal Tumors of Intermediate Differentiation, Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma), Breast Cancer, Bronchial Tumors, Burkitt Lymphoma, Basal Cell Carcinoma, Bile Duct Cancer (including Extrahepatic), Bladder Cancer, Bone Cancer (including Osteosarcoma and Malignant Fibrous Histiocytoma), Carcinoid Tumor, Carcinoma of Unknown Primary, Central Nervous System (such as Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumors and Lymphoma), Cervical Cancer, Childhood Cancers, Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Chronic Myeloproliferative Disorders, Colon Cancer, Colorectal Cancer, Craniopharyngioma, Cutaneous T-Cell Lymphoma (Mycosis Fungoides and Sézary Syndrome), Duct, Bile (Extrahepatic), Ductal

Carcinoma In Situ (DCIS), Embryonal Tumors (Central Nervous System), Endometrial Cancer, Ependymoblastoma, Ependymoma, Esophageal Cancer, Esthesioneuroblastoma, Ewing Sarcoma Family of Tumors, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer (like Intraocular Melanoma, Retinoblastoma), Fibrous Histiocytoma of Bone (including Malignant and Osteosarcoma), Gallbladder Cancer, Gastric (Stomach) Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumors (GIST), Germ Cell Tumor (Extracranial, Extragonadal, Ovarian), Gestational Trophoblastic Tumor, Glioma, Hairy Cell Leukemia, Head and Neck Cancer, Heart Cancer, Hepatocellular (Liver) Cancer, Histiocytosis, Langerhans Cell, Hodgkin Lymphoma, Hypopharyngeal Cancer, Intraocular Melanoma, Islet Cell Tumors (Endocrine, Pancreas), Kaposi Sarcoma, Kidney (including Renal Cell), Langerhans Cell Histiocytosis, Laryngeal Cancer, Leukemia (including Acute Lymphoblastic (ALL), Acute Myeloid (AML), Chronic Lymphocytic (CLL), Chronic Myelogenous (CML), Hairy Cell), Lip and Oral Cavity Cancer, Liver Cancer (Primary), Lobular Carcinoma In Situ (LCIS), Lung Cancer (Non-Small Cell and Small Cell), Lymphoma (AIDS-Related, Burkitt, Cutaneous T-Cell (Mycosis Fungoides and Sézary Syndrome), Hodgkin, Non-Hodgkin, Primary Central Nervous System (CNS), Macroglobulinemia, Waldenström, Male Breast Cancer, Malignant Fibrous Histiocytoma of Bone and Osteosarcoma, Medulloblastoma, Medulloepithelioma, Melanoma (including Intraocular (Eye)), Merkel Cell Carcinoma, Mesothelioma (Malignant), Metastatic Squamous Neck Cancer with Occult Primary, Midline Tract Carcinoma Involving NUT Gene, Mouth Cancer, Multiple Endocrine Neoplasia Syndromes, Multiple Myeloma/Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Myelogenous Leukemia, Chronic (CML), Myeloid Leukemia, Acute (AML), Myeloma and Multiple Myeloma, Myeloproliferative Disorders (Chronic), Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cancer, Oral Cavity Cancer, Lip and, Oropharyngeal Cancer, Osteosarcoma and Malignant Fibrous Histiocytoma of Bone, Ovarian Cancer (such as Epithelial, Germ Cell Tumor, Low Malignant Potential Tumor and High Grade Serous Ovarian Cancer), Pancreatic Cancer (including Islet Cell Tumors), Papillomatosis, Paraganglioma, Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumors of Intermediate Differentiation, Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Pleuropulmonary Blastoma, Pregnancy and Breast

Cancer, Primary Central Nervous System (CNS) Lymphoma, Prostate Cancer, Rectal Cancer, Renal Cell (Kidney) Cancer, Renal Pelvis and Ureter, Transitional Cell Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcoma (like Ewing Sarcoma Family of Tumors, Kaposi, Soft Tissue, Uterine), Sézary Syndrome, Skin Cancer (such as Melanoma, Merkel Cell Carcinoma, Nonmelanoma), Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Neck Cancer with Occult Primary, Metastatic, Stomach (Gastric) Cancer, Supratentorial Primitive Neuroectodermal Tumors, T-Cell Lymphoma (Cutaneous, Mycosis Fungoides and Sézary Syndrome), Testicular Cancer, Throat Cancer, Thymoma and Thymic Carcinoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Trophoblastic Tumor (Gestational), Unknown Primary, Unusual Cancers of Childhood, Ureter and Renal Pelvis, Transitional Cell Cancer, Urethral Cancer, Uterine Cancer, Endometrial, Uterine Sarcoma, Waldenström Macroglobulinemia and Wilms Tumor, or a variant thereof.

[0145] In certain embodiments, the cancer is chosen from small cell lung cancer, non small cell lung cancer, lung adenocarcinoma, colorectal cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, stomach cancer, and uterine cancer.

[0146] Also provided is a pharmaceutical composition comprising a compound as disclosed herein, together with a pharmaceutically acceptable carrier.

[0147] In certain embodiments, the pharmaceutical composition is formulated for oral administration. In certain embodiments, the pharmaceutical composition is formulated for parenteral administration. In certain embodiments, the pharmaceutical composition is formulated for intravenous administration. In certain embodiments, the pharmaceutical composition is formulated for intramuscular administration. In certain embodiments, the pharmaceutical composition is formulated for subcutaneous administration.

[0148] In certain embodiments, the oral pharmaceutical composition is chosen from a tablet and a capsule.

Definitions

[0149] As used herein, the terms below have the meanings indicated.

[0150] When ranges of values are disclosed, and the notation “from n_1 ... to n_2 ” or “between n_1 ... and n_2 ” is used, where n_1 and n_2 are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between

them. This range may be integral or continuous between and including the end values. By way of example, the range “from 2 to 6 carbons” is intended to include two, three, four, five, and six carbons, since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 μM (micromolar),” which is intended to include 1 μM , 3 μM , and everything in between to any number of significant figures (e.g., 1.255 μM , 2.1 μM , 2.9999 μM , etc.).

[0151] The term “about,” as used herein, is intended to qualify the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well, taking into account significant figures.

[0152] The term “acyl,” as used herein, alone or in combination, refers to a carbonyl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety where the atom attached to the carbonyl is carbon. An “acetyl” group refers to a $-\text{C}(\text{O})\text{CH}_3$ group. An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl and aroyl.

[0153] The term “alkenyl,” as used herein, alone or in combination, refers to a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkenyl will comprise from 2 to 6 carbon atoms. The term “alkenylene” refers to a carbon-carbon double bond system attached at two or more positions such as ethenylene $[(-\text{CH}=\text{CH}-), (-\text{C}::\text{C}-)]$. Examples of suitable alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl and the like. Unless otherwise specified, the term “alkenyl” may include “alkenylene” groups.

[0154] The term “alkoxy,” as used herein, alone or in combination, refers to an alkyl ether radical, wherein the term alkyl is as defined below. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, and the like.

[0155] The term “alkyl,” as used herein, alone or in combination, refers to a straight-chain or branched-chain alkyl radical containing from 1 to 20 carbon atoms. In certain embodiments, said alkyl will comprise from 1 to 10 carbon atoms. In further embodiments, said alkyl will comprise from 1 to 8 carbon atoms. Alkyl groups may be optionally substituted as defined herein. Examples of alkyl radicals include methyl, ethyl, n-propyl,

isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, noyl and the like. The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene

(-CH₂-). Unless otherwise specified, the term “alkyl” may include “alkylene” groups.

[0156] The term “alkylamino,” as used herein, alone or in combination, refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups may be mono- or dialkylated, forming groups such as, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino and the like.

[0157] The term “alkylidene,” as used herein, alone or in combination, refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.

[0158] The term “alkylthio,” as used herein, alone or in combination, refers to an alkyl thioether (R-S-) radical wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized. Examples of suitable alkyl thioether radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.

[0159] The term “alkynyl,” as used herein, alone or in combination, refers to a straight-chain or branched chain hydrocarbon radical having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, said alkynyl comprises from 2 to 4 carbon atoms. The term “alkynylene” refers to a carbon-carbon triple bond attached at two positions such as ethynylene (-C:::C-,

-C≡C-). Examples of alkynyl radicals include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, 3-methylbutyn-1-yl, hexyn-2-yl, and the like. Unless otherwise specified, the term “alkynyl” may include “alkynylene” groups.

[0160] The terms “amido” and “carbamoyl,” as used herein, alone or in combination, refer to an amino group as described below attached to the parent molecular moiety through a carbonyl group, or vice versa. The term “C-amido” as used herein, alone or in combination, refers to a -C(O)N(RR') group with R and R' as defined herein or as defined by the specifically enumerated “R” groups designated. The term “N-amido” as used herein, alone or in combination, refers to a RC(O)N(R')- group, with R and R' as defined herein or as defined by the specifically enumerated “R” groups designated. The term “acylamino” as used herein,

alone or in combination, embraces an acyl group attached to the parent moiety through an amino group. An example of an "acylamino" group is acetylamino ($\text{CH}_3\text{C}(\text{O})\text{NH}-$).

[0161] The term "amino," as used herein, alone or in combination, refers to $-\text{NRR}'$, wherein R and R' are independently chosen from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. Additionally, R and R' may combine to form heterocycloalkyl, either of which may be optionally substituted.

[0162] The term "aryl," as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together. The term "aryl" embraces aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthryl.

[0163] The term "arylalkenyl" or "aralkenyl," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.

[0164] The term "arylalkoxy" or "aralkoxy," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.

[0165] The term "arylalkyl" or "aralkyl," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group.

[0166] The term "arylalkynyl" or "aralkynyl," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.

[0167] The term "arylalkanoyl" or "aralkanoyl" or "aroyl," as used herein, alone or in combination, refers to an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as benzoyl, naphthoyl, phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.

[0168] The term aryloxy as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an oxy.

[0169] The terms "benzo" and "benz," as used herein, alone or in combination, refer to the divalent radical $\text{C}_6\text{H}_4=$ derived from benzene. Examples include benzothiophene and benzimidazole.

[0170] The term "carbamate," as used herein, alone or in combination, refers to an ester of carbamic acid ($-\text{NHCOO}-$) which may be attached to the parent molecular moiety from either the nitrogen or acid end, and which may be optionally substituted as defined herein.

[0171] The term "O-carbamyl" as used herein, alone or in combination, refers to a $-\text{OC}(\text{O})\text{NRR}'$, group-with R and R' as defined herein.

[0172] The term “N-carbamyl” as used herein, alone or in combination, refers to a ROC(O)NR’- group, with R and R’ as defined herein.

[0173] The term “carbonyl,” as used herein, when alone includes formyl [-C(O)H] and in combination is a -C(O)- group.

[0174] The term “carboxyl” or “carboxy,” as used herein, refers to -C(O)OH or the corresponding “carboxylate” anion, such as is in a carboxylic acid salt. An “O-carboxy” group refers to a RC(O)O- group, where R is as defined herein. A “C-carboxy” group refers to a -C(O)OR groups where R is as defined herein.

[0175] The term “cyano,” as used herein, alone or in combination, refers to -CN.

[0176] The term “cycloalkyl,” or, alternatively, “carbocycle,” as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is optionally substituted as defined herein. In certain embodiments, said cycloalkyl will comprise from 5 to 7 carbon atoms. Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl and the like. “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring systems, such as decahydronaphthalene, octahydronaphthalene as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type of isomer is exemplified in general by, bicyclo[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane.

[0177] The term “ester,” as used herein, alone or in combination, refers to a carboxy group bridging two moieties linked at carbon atoms.

[0178] The term “ether,” as used herein, alone or in combination, refers to an oxy group bridging two moieties linked at carbon atoms.

[0179] The term “halo,” or “halogen,” as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine.

[0180] The term “haloalkoxy,” as used herein, alone or in combination, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.

[0181] The term “haloalkyl,” as used herein, alone or in combination, refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of

the same halo atoms or a combination of different halo radicals. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.

“Haloalkylene” refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene

(-CFH-), difluoromethylene (-CF₂-), chloromethylene (-CHCl-) and the like.

[0182] The term "heteroalkyl," as used herein, alone or in combination, refers to a stable straight or branched chain, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms chosen from N, O, and S, and wherein the N and S atoms may optionally be oxidized and the N heteroatom may optionally be quaternized. The heteroatom(s) may be placed at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, -CH₂-NH-OCH₃.

[0183] The term "heteroaryl," as used herein, alone or in combination, refers to a 3 to 15 membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which contains at least one atom chosen from N, O, and S. In certain embodiments, said heteroaryl will comprise from 1 to 4 heteroatoms as ring members. In further embodiments, said heteroaryl will comprise from 1 to 2 heteroatoms as ring members. In certain embodiments, said heteroaryl will comprise from 5 to 7 atoms. The term also embraces fused polycyclic groups wherein heterocyclic rings are fused with aryl rings, wherein heteroaryl rings are fused with other heteroaryl rings, wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indoliziny, benzimidazolyl, quinolyl, isoquinolyl, quinoxaliny, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like.

[0184] The terms “heterocycloalkyl” and, interchangeably, “heterocycle,” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated (but nonaromatic) monocyclic, bicyclic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each said heteroatom may be independently chosen from nitrogen, oxygen, and sulfur. In certain embodiments, said heterocycloalkyl will comprise from 1 to 4 heteroatoms as ring members. In further embodiments, said heterocycloalkyl will comprise from 1 to 2 heteroatoms as ring members. In certain embodiments, said heterocycloalkyl will comprise from 3 to 8 ring members in each ring. In further embodiments, said heterocycloalkyl will comprise from 3 to 7 ring members in each ring. In yet further embodiments, said heterocycloalkyl will comprise from 5 to 6 ring members in each ring. “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic fused and benzo fused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group. Examples of heterocycle groups include aziridinyl, azetidiny, 1,3-benzodioxolyl, dihydroisindolyl, dihydroisoquinoliny, dihydrocinnoliny, dihydrobenzodioxiny, dihydro[1,3]oxazolo[4,5-b]pyridiny, benzothiazolyl, dihydroindolyl, dihy-dropyridiny, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindoliny, morpholiny, piperaziny, pyrrolidiny, tetrahydropyridiny, piperidiny, thiomorpholiny, and the like. The heterocycle groups may be optionally substituted unless specifically prohibited.

[0185] The term “hydraziny” as used herein, alone or in combination, refers to two amino groups joined by a single bond, i.e., -N-N-.

[0186] The term “hydroxy,” as used herein, alone or in combination, refers to -OH.

[0187] The term “hydroxyalkyl,” as used herein, alone or in combination, refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.

[0188] The term “imino,” as used herein, alone or in combination, refers to =N-.

[0189] The term “iminohydroxy,” as used herein, alone or in combination, refers to =N(OH) and =N-O-.

[0190] The phrase “in the main chain” refers to the longest contiguous or adjacent chain of carbon atoms starting at the point of attachment of a group to the compounds of any one of the formulas disclosed herein.

[0191] The term “isocyanato” refers to a -NCO group.

[0192] The term “isothiocyanato” refers to a -NCS group.

- [0193] The phrase “linear chain of atoms” refers to the longest straight chain of atoms independently chosen from carbon, nitrogen, oxygen and sulfur.
- [0194] The term “lower,” as used herein, alone or in a combination, where not otherwise specifically defined, means containing from 1 to and including 6 carbon atoms (i.e., C₁-C₆ alkyl).
- [0195] The term “lower aryl,” as used herein, alone or in combination, means phenyl or naphthyl, either of which may be optionally substituted as provided.
- [0196] The term “lower heteroaryl,” as used herein, alone or in combination, means either 1) monocyclic heteroaryl comprising five or six ring members, of which between one and four said members may be heteroatoms chosen from N, O, and S, or 2) bicyclic heteroaryl, wherein each of the fused rings comprises five or six ring members, comprising between them one to four heteroatoms chosen from N, O, and S.
- [0197] The term “lower cycloalkyl,” as used herein, alone or in combination, means a monocyclic cycloalkyl having between three and six ring members (i.e., C₃-C₆ cycloalkyl). Lower cycloalkyls may be unsaturated. Examples of lower cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- [0198] The term “lower heterocycloalkyl,” as used herein, alone or in combination, means a monocyclic heterocycloalkyl having between three and six ring members, of which between one and four may be heteroatoms chosen from N, O, and S (i.e., C₃-C₆ heterocycloalkyl). Examples of lower heterocycloalkyls include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl. Lower heterocycloalkyls may be unsaturated.
- [0199] The term “lower amino,” as used herein, alone or in combination, refers to -NRR', wherein R and R' are independently chosen from hydrogen and lower alkyl, either of which may be optionally substituted.
- [0200] The term “mercaptyl” as used herein, alone or in combination, refers to an RS-group, where R is as defined herein.
- [0201] The term “nitro,” as used herein, alone or in combination, refers to -NO₂.
- [0202] The terms “oxy” or “oxa,” as used herein, alone or in combination, refer to -O-.
- [0203] The term “oxo,” as used herein, alone or in combination, refers to =O.
- [0204] The term “perhaloalkoxy” refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms.
- [0205] The term “perhaloalkyl” as used herein, alone or in combination, refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.

[0206] The terms “sulfonate,” “sulfonic acid,” and “sulfonic,” as used herein, alone or in combination, refer the $-\text{SO}_3\text{H}$ group and its anion as the sulfonic acid is used in salt formation.

[0207] The term “sulfanyl,” as used herein, alone or in combination, refers to $-\text{S}-$.

[0208] The term “sulfinyl,” as used herein, alone or in combination, refers to $-\text{S}(\text{O})-$.

[0209] The term “sulfonyl,” as used herein, alone or in combination, refers to $-\text{S}(\text{O})_2-$.

[0210] The term “N-sulfonamido” refers to a $\text{RS}(=\text{O})_2\text{NR}'$ - group with R and R' as defined herein.

[0211] The term “S-sulfonamido” refers to a $-\text{S}(=\text{O})_2\text{NRR}'$, group, with R and R' as defined herein.

[0212] The terms “thia” and “thio,” as used herein, alone or in combination, refer to a $-\text{S}-$ group or an ether wherein the oxygen is replaced with sulfur. The oxidized derivatives of the thio group, namely sulfinyl and sulfonyl, are included in the definition of thia and thio.

[0213] The term “thiol,” as used herein, alone or in combination, refers to an $-\text{SH}$ group.

[0214] The term “thiocarbonyl,” as used herein, when alone includes thioformyl $-\text{C}(\text{S})\text{H}$ and in combination is a $-\text{C}(\text{S})-$ group.

[0215] The term “N-thiocarbamyl” refers to an $\text{ROC}(\text{S})\text{NR}'-$ group, with R and R' as defined herein.

[0216] The term “O-thiocarbamyl” refers to a $-\text{OC}(\text{S})\text{NRR}'$, group with R and R' as defined herein.

[0217] The term “thiocyanato” refers to a $-\text{CNS}$ group.

[0218] The term “trihalomethanesulfonamido” refers to a $\text{X}_3\text{CS}(\text{O})_2\text{NR}-$ group with X is a halogen and R as defined herein.

[0219] The term “trihalomethanesulfonyl” refers to a $\text{X}_3\text{CS}(\text{O})_2-$ group where X is a halogen.

[0220] The term “trihalomethoxy” refers to a $\text{X}_3\text{CO}-$ group where X is a halogen.

[0221] The term “trisubstituted silyl,” as used herein, alone or in combination, refers to a silicone group substituted at its three free valences with groups as listed herein under the definition of substituted amino. Examples include trimethylsilyl, tert-butyl dimethylsilyl, triphenylsilyl and the like.

[0222] Any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is that which attaches to the parent moiety. For example, the composite group

alkylamido would represent an alkyl group attached to the parent molecule through an amido group, and the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.

[0223] When a group is defined to be “null,” what is meant is that said group is absent.

[0224] The term “optionally substituted” means the anteceding group may be substituted or unsubstituted. When substituted, the substituents of an “optionally substituted” group may include, without limitation, one or more substituents independently chosen from the following groups or a particular designated set of groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio, sulfonate, sulfonic acid, trisubstituted silyl, N_3 , SH, SCH₃, C(O)CH₃, CO₂CH₃, CO₂H, pyridinyl, thiophene, furanyl, lower carbamate, and lower urea. Where structurally feasible, two substituents may be joined together to form a fused five-, six-, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms, for example forming methylenedioxy or ethylenedioxy. An optionally substituted group may be unsubstituted (e.g., -CH₂CH₃), fully substituted (e.g., -CF₂CF₃), monosubstituted (e.g., -CH₂CH₂F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., -CH₂CF₃). Where substituents are recited without qualification as to substitution, both substituted and unsubstituted forms are encompassed. Where a substituent is qualified as “substituted,” the substituted form is specifically intended. Additionally, different sets of optional substituents to a particular moiety may be defined as needed; in these cases, the optional substitution will be as defined, often immediately following the phrase, “optionally substituted with.”

[0225] The term R or the term R', appearing by itself and without a number designation, unless otherwise defined, refers to a moiety chosen from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted. Such R and R' groups should be understood to be optionally substituted as defined herein. Whether an R group has a number designation or not, every R group, including R, R' and Rⁿ where n=(1, 2, 3, ...n), every substituent, and every term should be understood to be independent of every other in terms of selection from a group. Should any

variable, substituent, or term (e.g. aryl, heterocycle, R, etc.) occur more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence. Those of skill in the art will further recognize that certain groups may be attached to a parent molecule or may occupy a position in a chain of elements from either end as written. For example, an unsymmetrical group such as -C(O)N(R)- may be attached to the parent moiety at either the carbon or the nitrogen.

[0226] Asymmetric centers exist in the compounds disclosed herein. These centers are designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the disclosure encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and l-isomers, and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. Additionally, the compounds disclosed herein may exist as geometric isomers. The present disclosure includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof. Additionally, compounds may exist as tautomers; all tautomeric isomers are provided by this disclosure. Additionally, the compounds disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms.

[0227] The term “bond” refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. A bond may be single, double, or triple unless otherwise specified. A dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position.

[0228] The term “disease” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.

[0229] The term "combination therapy" means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.

[0230] "HER2 inhibitor" is used herein to refer to a compound that exhibits an IC₅₀ with respect to HER2 activity of no more than about 100 μM and more typically not more than about 50 μM, as measured in the HER2 assay described generally herein. "IC₅₀" is that concentration of inhibitor which reduces the activity of an enzyme (e.g., HER2) to half-maximal level. Certain compounds disclosed herein have been discovered to exhibit inhibition against HER2. In certain embodiments, compounds will exhibit an IC₅₀ with respect to HER2 of no more than about 10 μM; in further embodiments, compounds will exhibit an IC₅₀ with respect to HER2 of no more than about 1 μM; in yet further embodiments, compounds will exhibit an IC₅₀ with respect to HER2 of not more than about 200 nM; in yet further embodiments, compounds will exhibit an IC₅₀ with respect to HER2 of not more than about 50 nM, as measured in the HER2 assay described herein.

[0231] Certain compounds display selectivity for certain mutant forms of HER2 over WT EGFR. For certain compounds and certain mutants, the mutant HER2 selectivity, quantified as the ratio IC₅₀ (HER2 mutant) / IC₅₀ (WT EGFR) is 0.5 or lower. For certain compounds and certain mutants, the mutant HER2 selectivity is 0.2 or lower. For certain compounds and certain mutants, the mutant HER2 selectivity is 0.1 or lower.

[0232] "EGFR2 inhibitor" is used herein to refer to a compound that exhibits an IC₅₀ with respect to EGFR activity of no more than about 100 μM and more typically not more than about 50 μM, as measured in the EGFR assay described generally herein. "IC₅₀" is that concentration of inhibitor which reduces the activity of an enzyme (e.g., EGFR) to half-maximal level. Certain compounds disclosed herein have been discovered to exhibit inhibition against EGFR. In certain embodiments, compounds will exhibit an IC₅₀ with respect to EGFR of no more than about 10 μM; in further embodiments, compounds will exhibit an IC₅₀ with respect to EGFR of no more than about 1 μM; in yet further embodiments, compounds will exhibit an IC₅₀ with respect to EGFR of not more than about

200 nM; in yet further embodiments, compounds will exhibit an IC₅₀ with respect to EGFR of not more than about 50 nM, as measured in the EGFR assay described herein.

[0233] Certain compounds display selectivity for certain mutant forms of EGFR over WT EGFR. For certain compounds and certain mutants, the mutant EGFR selectivity, quantified as the ratio IC₅₀ (EGFRmutant) / IC₅₀ (WT EGFR) is 0.5 or lower. For certain compounds and certain mutants, the mutant EGFR selectivity is 0.2 or lower. For certain compounds and certain mutants, the mutant EGFR selectivity is 0.1 or lower.

[0234] The phrase "therapeutically effective" is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder or on the effecting of a clinical endpoint.

[0235] The term "therapeutically acceptable" refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.

[0236] As used herein, reference to "treatment" of a patient is intended to include prophylaxis. Treatment may also be preemptive in nature, i.e., it may include prevention of disease. Prevention of a disease may involve complete protection from disease, for example as in the case of prevention of infection with a pathogen, or may involve prevention of disease progression. For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level. Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.

[0237] The term "patient" is generally synonymous with the term "subject" and includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.

[0238] The term "prodrug" refers to a compound that is made more active in vivo. Certain compounds disclosed herein may also exist as prodrugs, as described in *Hydrolysis in Drug and Prodrug Metabolism : Chemistry, Biochemistry, and Enzymology* (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound. Additionally, prodrugs can be converted to the compound by chemical or biochemical methods in an ex

vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound which is administered as an ester (the "prodrug"), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.

[0239] The compounds disclosed herein can exist as therapeutically acceptable salts. The present disclosure includes compounds listed above in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. For a more complete discussion of the preparation and selection of salts, refer to *Pharmaceutical Salts: Properties, Selection, and Use* (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).

[0240] The term "therapeutically acceptable salt," as used herein, represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate,

trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the present disclosure contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.

[0241] Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, *N,N*-dimethylaniline, *N*-methylpiperidine, *N*-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, *N,N*-dibenzylphenethylamine, 1-phenamine, and *N,N'*-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

Pharmaceutical Compositions

[0242] While it may be possible for the compounds of the subject disclosure to be administered as the raw chemical, it is also possible to present them as a pharmaceutical formulation. Accordingly, provided herein are pharmaceutical formulations which comprise one or more of certain compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art. The

pharmaceutical compositions disclosed herein may be manufactured in any manner known in the art, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.

[0243] The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound of the subject disclosure or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

Oral Administration

[0244] The compounds of the present disclosure may be administered orally, including swallowing, so the compound enters the gastrointestinal tract, or is absorbed into the blood stream directly from the mouth, including sublingual or buccal administration.

[0245] Suitable compositions for oral administration include solid formulations such as tablets, pills, cachets, lozenges and hard or soft capsules, which can contain liquids, gels, powders, or granules, solutions or suspensions in an aqueous liquid or a non-aqueous liquid, or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

[0246] In a tablet or capsule dosage form the amount of drug present may be from about 0.05% to about 95% by weight, more typically from about 2% to about 50% by weight of the dosage form.

[0247] In addition, tablets or capsules may contain a disintegrant, comprising from about 0.5% to about 35% by weight, more typically from about 2% to about 25% of the dosage form. Examples of disintegrants include methyl cellulose, sodium or calcium carboxymethyl cellulose, croscarmellose sodium, polyvinylpyrrolidone, hydroxypropyl cellulose, starch and the like.

[0248] Suitable binders, for use in a tablet, include gelatin, polyethylene glycol, sugars, gums, starch, hydroxypropyl cellulose and the like. Suitable diluents, for use in a tablet, include mannitol, xylitol, lactose, dextrose, sucrose, sorbitol and starch.

[0249] Suitable surface active agents and glidants, for use in a tablet or capsule, may be present in amounts from about 0.1% to about 3% by weight, and include polysorbate 80, sodium dodecyl sulfate, talc and silicon dioxide.

[0250] Suitable lubricants, for use in a tablet or capsule, may be present in amounts from about 0.1% to about 5% by weight, and include calcium, zinc or magnesium stearate, sodium stearyl fumarate and the like.

[0251] Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with a liquid diluent. Dyes or pigments may be added to tablets for identification or to characterize different combinations of active compound doses.

[0252] Liquid formulations can include emulsions, solutions, syrups, elixirs and suspensions, which can be used in soft or hard capsules. Such formulations may include a pharmaceutically acceptable carrier, for example, water, ethanol, polyethylene glycol, cellulose, or an oil. The formulation may also include one or more emulsifying agents and/or suspending agents.

[0253] Compositions for oral administration may be formulated as immediate or modified release, including delayed or sustained release, optionally with enteric coating.

[0254] In another embodiment, a pharmaceutical composition comprises a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0255] Pharmaceutical preparations which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally

be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Parenteral Administration

[0256] Compounds of the present disclosure may be administered directly into the blood stream, muscle, or internal organs by injection, e.g., by bolus injection or continuous infusion. Suitable means for parenteral administration include intravenous, intra-muscular, subcutaneous intraarterial, intraperitoneal, intrathecal, intracranial, and the like. Suitable devices for parenteral administration include injectors (including needle and needle-free injectors) and infusion methods. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials.

[0257] Most parenteral formulations are aqueous solutions containing excipients, including salts, buffering, suspending, stabilizing and/or dispersing agents, antioxidants, bacteriostats, preservatives, and solutes which render the formulation isotonic with the blood of the intended recipient, and carbohydrates.

[0258] Parenteral formulations may also be prepared in a dehydrated form (e.g., by lyophilization) or as sterile non-aqueous solutions. These formulations can be used with a suitable vehicle, such as sterile water. Solubility-enhancing agents may also be used in preparation of parenteral solutions. Compositions for parenteral administration may be formulated as immediate or modified release, including delayed or sustained release. Compounds may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable

polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0259] The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

[0260] Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0261] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Topical Administration

[0262] Compounds of the present disclosure may be administered topically (for example to the skin, mucous membranes, ear, nose, or eye) or transdermally. Formulations for topical administration can include, but are not limited to, lotions, solutions, creams, gels, hydrogels,

ointments, foams, implants, patches and the like. Carriers that are pharmaceutically acceptable for topical administration formulations can include water, alcohol, mineral oil, glycerin, polyethylene glycol and the like. Topical administration can also be performed by, for example, electroporation, iontophoresis, phonophoresis and the like.

[0263] Typically, the active ingredient for topical administration may comprise from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w; less than 5% w/w; from 2% w/w to 5% w/w; or from 0.1% to 1% w/w of the formulation.

[0264] Compositions for topical administration may be formulated as immediate or modified release, including delayed or sustained release.

[0265] Certain compounds disclosed herein may be administered topically, that is by non-systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.

[0266] Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation.

Rectal, Buccal, and Sublingual Administration

[0267] Suppositories for rectal administration of the compounds of the present disclosure can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug.

[0268] For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner. Such compositions

may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.

[0269] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.

Administration by Inhalation

[0270] For administration by inhalation, compounds may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds according to the disclosure may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.

[0271] Other carrier materials and modes of administration known in the pharmaceutical art may also be used. Pharmaceutical compositions of the disclosure may be prepared by any of the well-known techniques of pharmacy, such as effective formulation and administration procedures. Preferred unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.

[0272] It should be understood that in addition to the ingredients particularly mentioned above, the formulations described above may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

[0273] Compounds may be administered orally or via injection at a dose of from 0.1 to 500 mg/kg per day. The dose range for adult humans is generally from 5 mg to 2 g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.

[0274] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

[0275] The compounds can be administered in various modes, *e.g.* orally, topically, or by injection. The precise amount of compound administered to a patient will be the responsibility of the attendant physician. The specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated. In addition, the route of administration may vary depending on the condition and its severity. The above considerations concerning effective formulations and administration procedures are well known in the art and are described in standard textbooks.

[0276] Preferred unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.

[0277] It should be understood that in addition to the ingredients particularly mentioned above, the formulations described above may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

[0278] Compounds may be administered orally or via injection at a dose of from 0.1 to 500 mg/kg per day. The dose range for adult humans is generally from 5 mg to 2 g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.

[0279] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

[0280] The compounds can be administered in various modes, *e.g.* orally, topically, or by injection. The precise amount of compound administered to a patient will be the responsibility of the attendant physician. The specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the

severity of the indication or condition being treated. Also, the route of administration may vary depending on the condition and its severity.

Combinations and Combination Therapy

[0281] In certain instances, it may be appropriate to administer at least one of the compounds described herein (or a pharmaceutically acceptable salt, ester, or prodrug thereof) in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient upon receiving one of the compounds herein is hypertension, then it may be appropriate to administer an anti-hypertensive agent in combination with the initial therapeutic agent. Or, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). Or, by way of example only, the benefit of experienced by a patient may be increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit. By way of example only, in a treatment for diabetes involving administration of one of the compounds described herein, increased therapeutic benefit may result by also providing the patient with another therapeutic agent for diabetes. In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.

[0282] In another aspect, a compound with EGFR or HER2 inhibitory properties, as disclosed herein, is optionally used in combination with procedures that provide additional benefit to the patient. The inhibitor and any additional therapies are optionally administered before, during, or after the occurrence of a disease or condition, and the timing of administering the composition containing the inhibitor varies in some embodiments. Thus, for example, the inhibitor may be used as a prophylactic and is administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition. The inhibitor and compositions are optionally administered to a subject during or as soon as possible after the onset of the symptoms.

[0283] a compound with EGFR or HER2 inhibitory properties, as disclosed herein, can be used in combination with anti-cancer drugs, including but not limited to the following classes: alkylating agents, anti-metabolites, plant alkaloids and terpenoids, topoisomerase inhibitors, cytotoxic antibiotics, angiogenesis inhibitors and tyrosine kinase inhibitors.

[0284] For use in the treatment or attenuation of cancer and neoplastic diseases, a compound with EGFR or HER2 inhibitory properties, as disclosed herein, may be optimally used together with one or more of the following non-limiting examples of anti-cancer agents, including, but not limited to:

- 1) inhibitors or modulators of a protein involved in one or more of the DNA damage repair (DDR) pathways such as:
 - a. PARP1/2, including, but not limited to: olaparib, niraparib, rucaparib;
 - b. checkpoint kinase 1 (CHK1), including, but not limited to: UCN-01, AZD7762, PF477736, SCH900776, MK-8776, LY2603618, V158411, and EXEL-9844;
 - c. checkpoint kinase 2 (CHK2), including, but not limited to: PV1019, NSC 109555, and VRX0466617;
 - d. dual CHK1 / CHK2, including, but not limited to: XL-844, AZD7762, and PF-473336;
 - e. WEE1, including, but not limited to: MK-1775 and PD0166285;
 - f. ATM, including, but not limited to KU-55933,
 - g. DNA-dependent protein kinase, including, but not limited to NU7441 and M3814; and
 - h. Additional proteins involved in DDR;
- 2) Inhibitors or modulators of one or more immune checkpoints, including, but not limited to:
 - a. PD-1 inhibitors such as nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), pidilizumab (CT-011), and AMP-224 (AMPLIMMUNE);
 - b. PD-L1 inhibitors such as Atezolizumab (TECENTRIQ), Avelumab (Bavencio), Durvalumab (Imfinzi), MPDL3280A (Tecentriq), BMS-936559, and MEDI4736;
 - c. anti-CTLA-4 antibodies such as ipilimumab (YERVOY) and CP-675,206 (TREMELIMUMAB);
 - d. inhibitors of T-cell immunoglobulin and mucin domain 3 (Tim-3);
 - e. inhibitors of V-domain Ig suppressor of T cell activation (Vista);
 - f. inhibitors of band T lymphocyte attenuator (BTLA);
 - g. inhibitors of lymphocyte activation gene 3 (LAG3); and
 - h. inhibitors of T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT);

- 3) telomerase inhibitors or telomeric DNA binding compounds;
- 4) alkylating agents, including, but not limited to: chlorambucil (LEUKERAN), oxaliplatin (ELOXATIN), streptozocin (ZANOSAR), dacarbazine, ifosfamide, lomustine (CCNU), procarbazine (MATULAN), temozolomide (TEMODAR), and thiotepa;
- 5) DNA crosslinking agents, including, but not limited to: carmustine, chlorambucil (LEUKERAN), carboplatin (PARAPLATIN), cisplatin (PLATIN), busulfan (MYLERAN), melphalan (ALKERAN), mitomycin (MITOSOL), and cyclophosphamide (ENDOXAN);
- 6) anti-metabolites, including, but not limited to: cladribine (LEUSTATIN), cytarbine, (ARA-C), mercaptopurine (PURINETHOL), thioguanine, pentostatin (NIPENT), cytosine arabinoside (cytarabine, ARA-C), gemcitabine (GEMZAR), fluorouracil (5-FU, CARAC), capecitabine (XELODA), leucovorin (FUSILEV), methotrexate (RHEUMATREX), and raltitrexed;
- 7) antimitotics, which are often plant alkaloids and terpenoids, or derivatives thereof including but not limited to: taxanes such as docetaxel (TAXITERE), paclitaxel (ABRAXANE, TAXOL), vinca alkaloids such as vincristine (ONCOVIN), vinblastine, vindesine, and vinorelbine (NAVELBINE);
- 8) topoisomerase inhibitors, including, but not limited to: amsacrine, camptothecin (CTP), genisten, irinotecan (CAMPTOSAR), topotecan (HYCAMTIN), doxorubicin (ADRIAMYCIN), daunorubicin (CERUBIDINE), epirubicin (ELLENCE), ICRF-193, teniposide (VUMON), mitoxantrone (NOVANTRONE), and etoposide (EPOSIN);
- 9) DNA replication inhibitors, including, but not limited to: fludarabine (FLUDARA), aphidicolin, ganciclovir, and cidofovir;
- 10) ribonucleoside diphosphate reductase inhibitors, including, but not limited to: hydroxyurea;
- 11) transcription inhibitors, including, but not limited to: actinomycin D (dactinomycin, COSMEGEN) and plicamycin (mithramycin);
- 12) DNA cleaving agents, including, but not limited to: bleomycin (BLENOXANE), idarubicin,
- 13) cytotoxic antibiotics, including, but not limited to: actinomycin D (dactinomycin, COSMEGEN),

- 14) aromatase inhibitors, including, but not limited to: aminoglutethimide, anastrozole (ARIMIDEX), letrozole (FEMARA), vorozole (RIVIZOR), and exemestane (AROMASIN);
- 15) angiogenesis inhibitors, including, but not limited to: genistein, sunitinib (SUTENT), and bevacizumab (AVASTIN);
- 16) anti-steroids and anti-androgens, including, but not limited to: aminoglutethimide (CYTADREN), bicalutamide (CASODEX), cyproterone, flutamide (EULEXIN), nilutamide(NILANDRON);
- 17) tyrosine kinase inhibitors, including, but not limited to: imatinib (GLEEVEC), erlotinib (TARCEVA), lapatinib (TYKERB), sorafenib (NEXAVAR), and axitinib (INLYTA);
- 18) mTOR inhibitors, including, but not limited to: everolimus, temsirolimus (TORISEL), and sirolimus;
- 19) monoclonal antibodies, including, but not limited to: trastuzumab (HERCEPTIN) and rituximab (RITUXAN);
- 20) apoptosis inducers such as cordycepin;
- 21) protein synthesis inhibitors, including, but not limited to: clindamycin, chloramphenicol, streptomycin, anisomycin, and cycloheximide;
- 22) antidiabetics, including, but not limited to: metformin and phenformin;
- 23) antibiotics, including, but not limited to:
 - a. tetracyclines, including, but not limited to: doxycycline;
 - b. erythromycins, including, but not limited to: azithromycin;
 - c. glycyglycines, including, but not limited to: tigecycline;
 - d. antiparasitics, including, but not limited to: pyriminium pamoate;
 - e. beta-lactams, including, but not limited to the penicillins and cephalosporins;
 - f. anthracycline antibiotics, including, but not limited to: daunorubicin and doxorubicin;
 - g. other antibiotics, including, but not limited to: chloramphenicol, mitomycin C, and actinomycin;
- 24) antibody therapeutical agents, including, but not limited to: muromonab-CD3, infliximab (REMICADE), adalimumab (HUMIRA), omalizumab (XOLAIR), daclizumab (ZENAPAX), rituximab (RITUXAN), ibritumomab (ZEVALIN), tositumomab (BEXXAR), cetuximab (ERBITUX), trastuzumab (HERCEPTIN),

ADCETRIS, alemtuzumab (CAMPATH-1H), Lym-1 (ONCOLYM), ipilimumab (YERVOY), vitaxin, bevacizumab (AVASTIN), and abciximab (REOPRO); and 25) other agents, such as Bacillus Calmette–Guérin (B-C-G) vaccine; buserelin (ETILAMIDE); chloroquine (ARALEN); clodronate, pamidronate, and other bisphosphonates; colchicine; demethoxyviridin; dichloroacetate; estramustine; filgrastim (NEUPOGEN); fludrocortisone (FLORINEF); goserelin (ZOLADEX); interferon; leucovorin; leuprolide (LUPRON); levamisole; lonidamine; mesna; metformin; mitotane (o,p'-DDD, LYSODREN); nocodazole; octreotide (SANDOSTATIN); perifosine; porfimer (particularly in combination with photo- and radiotherapy); suramin; tamoxifen; titanocene dichloride; tretinoin; anabolic steroids such as fluoxymesterone (HALOTESTIN); estrogens such as estradiol, diethylstilbestrol (DES), and dienestrol; progestins such as medroxyprogesterone acetate (MPA) and megestrol; and testosterone;

[0285] Where a subject is suffering from or at risk of suffering from an inflammatory condition, a compound with EGFR or HER2 inhibitory properties, as disclosed herein, is optionally used together with one or more agents or methods for treating an inflammatory condition in any combination. Therapeutic agents/treatments for treating an autoimmune and/or inflammatory condition include, but are not limited to any of the following examples:

- 1) corticosteroids, including but not limited to cortisone, dexamethasone, and methylprednisolone;
- 2) nonsteroidal anti-inflammatory drugs (NSAIDs), including but not limited to ibuprofen, naproxen, acetaminophen, aspirin, fenoprofen (NALFON), flurbiprofen (ANSAID), ketoprofen, oxaprozin (DAYPRO), diclofenac sodium (VOLTAREN), diclofenac potassium (CATAFLAM), etodolac (LODINE), indomethacin (INDOCIN), ketorolac (TORADOL), sulindac (CLINORIL), tolmetin (TOLECTIN), meclofenamate (MECLOMEN), mefenamic acid (PONSTEL), nabumetone (RELAFEN) and piroxicam (FELDENE);
- 3) immunosuppressants, including but not limited to methotrexate (RHEUMATREX), leflunomide (ARAVA), azathioprine (IMURAN), cyclosporine (NEORAL, SANDIMMUNE), tacrolimus and cyclophosphamide (CYTOXAN);
- 4) CD20 blockers, including but not limited to rituximab (RITUXAN);

- 5) Tumor Necrosis Factor (TNF) blockers, including but not limited to etanercept (ENBREL), infliximab (REMICADE) and adalimumab (HUMIRA);
- 6) interleukin-1 receptor antagonists, including but not limited to anakinra (KINERET);
- 7) interleukin-6 inhibitors, including but not limited to tocilizumab (ACTEMRA);
- 8) interleukin-17 inhibitors, including but not limited to AIN457;
- 9) Janus kinase inhibitors, including but not limited to tasocitinib; and
- 10) syk inhibitors, including but not limited to fostamatinib.

[0286] In any case, the multiple therapeutic agents (at least one of which is a compound disclosed herein) may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.

[0287] Besides being useful for human treatment, certain compounds and formulations disclosed herein may also be useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.

Compound Synthesis

[0288] Compounds of the present disclosure can be prepared using methods illustrated in general synthetic schemes and experimental procedures detailed below. General synthetic schemes and experimental procedures are presented for purposes of illustration and are not intended to be limiting. Starting materials used to prepare compounds of the present disclosure are commercially available or can be prepared using routine methods known in the art.

Abbreviations


[0289] Ac₂O = acetic anhydride; AcCl = acetyl chloride; AcOH = acetic acid; AIBN = azobisisobutyronitrile; aq. = aqueous; Bu₃SnH = tributyltin hydride; CD₃OD = deuterated methanol; CDCl₃ = deuterated chloroform; CDI = 1,1'-Carbonyldiimidazole; DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene; DCM = dichloromethane; DEAD = diethyl

azodicarboxylate; DIBAL-H = di-iso-butyl aluminium hydride; DIEA = DIPEA = N,N-diisopropylethylamine; DMAP = 4-dimethylaminopyridine; DMF = N,N-dimethylformamide; DMSO-d₆ = deuterated dimethyl sulfoxide; DMSO = dimethyl sulfoxide; DPPA = diphenylphosphoryl azide; EDC.HCl = EDCl.HCl = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; EGFR = HER1 = ErbB1 = human epidermal growth factor receptor); Et₂O = diethyl ether; EtOAc = ethyl acetate; EtOH = ethanol; h = hour; FACS = fluorescence activated cell sorting; FBS = fetal bovine serum; FITC = fluorescein isothiocyanate; HATU=2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium; HER2 = Neu = ErbB2 = human epidermal growth factor receptor 2; HMDS = hexamethyldisilazane; HOBT = 1-hydroxybenzotriazole; i-PrOH = isopropanol; IL-3 = interleukin-3; LAH = LiAlH₄ = lithium aluminium hydride; LiHMDS = Lithium bis(trimethylsilyl)amide; MeCN = acetonitrile; MeOH = methanol; MP-carbonate resin = macroporous triethylammonium methylpolystyrene carbonate resin; MsCl = mesyl chloride; MTBE = methyl tertiary butyl ether; MW = microwave irradiation ; n-BuLi = n-butyllithium; NaHMDS = Sodium bis(trimethylsilyl)amide; NaOMe = sodium methoxide; NaOtBu = sodium t-butoxide; NBS = N-bromosuccinimide; NCS = N-chlorosuccinimide; NMP = N-Methyl-2-pyrrolidone; Pd(Ph₃)₄ = tetrakis(triphenylphosphine)palladium(0); Pd₂(dba)₃ = tris(dibenzylideneacetone)-dipalladium(0); PdCl₂(PPh₃)₂ = bis(triphenylphosphine)palladium(II) dichloride; PE = phycoerythrin; PG = protecting group; prep-HPLC = preparative high-performance liquid chromatography; PyBop = (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate; Pyr = pyridine; RT = room temperature; RuPhos = 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl; sat. = saturated; ss = saturated solution; t-BuOH = tert-butanol; T3P = Propylphosphonic Anhydride; TBS = TBDMS = *tert*-butyldimethylsilyl; TBSCl = TBDMSCl = *tert*-butyldimethylchlorosilane; TEA = Et₃N = triethylamine; TFA = trifluoroacetic acid; TFAA = trifluoroacetic anhydride; THF = tetrahydrofuran; Tol = toluene; TsCl = p-toluenesulfonyl chloride = tosyl chloride; XPhos = 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl.

General Synthetic Methods for Preparing Compounds

The following schemes can be used to practice the present disclosure.


Scheme I



[0290] Examples 1-2 can be synthesized using the following general synthetic procedure set forth in Scheme I. Pyridine derivative **101** is converted to isonicotinic acid derivative **102** via a three step protection / carboxylation / deprotection sequence. The bicyclic pyrido[3,4-d]pyrimidine structure of **103** is then formed by condensation with formamide, which is then chlorinated to give dihalo compound **104**. Sequential reaction of this intermediate with first ArNH_2 , and then PMB-NH_2 (PMB = p-methoxybenzyl) gives disubstituted pyrido[3,4-d]-pyrimidine **106**. The PMB group is removed under acidic conditions, and the free primary amine is then coupled with 2-(diethoxyphosphoryl)acetic acid to give amide **108**. Reaction with 2-(dimethylamino)acetaldehyde (generated in situ from the acetal precursor **109**) gives butenamide product **110**.


[0291] The disclosure is further illustrated by the following examples.

EXAMPLE 1




(E)-N-(4-((3-Bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide

Step 1



[0292] **tert-Butyl (6-fluoropyridin-3-yl)carbamate** To a solution of 6-fluoropyridin-3-amine (2.8 g, 25 mmol) in 6mL of MTBE was added di-tert-butyl dicarbonate (21.8 g, 100 mmol) at room temperature. The mixture was stirred at 45 °C for 16 hrs. 1 gram of activated carbon was added and the mixture was stirred briefly and then filtered. The filtrate was purified by flash column chromatography eluting with PE/EA (2/1) to afford the title compound as a white solid (4.8 g, 90.6%). MS (ES+) $C_{10}H_{13}FN_2O_2$ requires: 212, found: 213 $[M+H]^+$.


Step 2



[0293] **5-((tert-Butoxycarbonyl)amino)-2-fluoroisonicotinic acid** To a mixture of the product from the previous step (500 mg, 2.36 mmol), TMEDA (0.88 mL) and MTBE (7 mL) was added a solution of n-BuLi (2.5 M in hexane, 2.36 mL) at -70 °C. After completion of the addition, the mixture was allowed to warm to -10 °C to -15 °C and held at this


temperature for 3 h. Dry CO₂ gas was sparged at -70 °C for 2 h. The mixture was heated to 5 °C and then water (6 mL) was added. The aqueous phase was collected and the organic phase was extracted with 1 M NaOH. To the combined aqueous layers was added 6 M HCl slowly to adjust the pH to 2.5–3.0. The resulting mixture was extracted with EtOAc. The organic layer was dried and concentrated. The crude product was washed with a small amount of EtOAc to afford the title compound (340 mg, 56.2%) as a white solid. MS (ES+) C₁₁H₁₃FN₂O₄ requires: 256, found: 257 [M+H]⁺.

Step 3




[0294] **5-Amino-2-fluoroisonicotinic acid** To a solution of the product from the previous step (1.9 g, 7.4 mmol) in DCM (8 mL) was added CF₃COOH (3.5 mL) at 0 °C. The resulting solution was stirred at room temperature for 3 h. The mixture was concentrated under vacuum to afford the title compound as a yellow solid (900 mg, 77.8%). MS (ES+) C₆H₅FN₂O₂ requires: 156, found: 157 [M+H]⁺.

Step 4




[0295] **6-Fluoropyrido[3,4-d]pyrimidin-4(3H)-one** A suspension of the product from the previous step (450 mg, 2.88 mmol) in formamide (5 mL) was heated at an internal temperature of 140 °C overnight with stirring. The mixture was cooled to room temperature, diluted with water (20 mL), and extracted with EtOAc. The organic layer was dried and concentrated. Water (5 mL) was added and the precipitate that formed was collected by filtration to afford the title compound (250 mg, 50.3%) as a yellow solid. MS (ES+) C₇H₄FN₃O, requires: 165, found: 166 [M+H]⁺.

Step 5




[0296] **4-Chloro-6-fluoropyrido[3,4-d]pyrimidine** A suspension of the product from the previous step (250 mg, 1.52 mmol) in SOCl_2 (5 mL) and DMF (1 drop) was refluxed for 2 h. The reaction mixture was evaporated to afford the title compound, which was used directly in the next step. MS (ES+) $\text{C}_7\text{H}_3\text{ClFN}_3$ requires: 183, found: 184 $[\text{M}+\text{H}]^+$.

Step 6




[0297] **N-(3-Bromo-4-chlorophenyl)-6-fluoropyrido[3,4-d]pyrimidin-4-amine** A mixture of the product from the previous step (244 mg, 1.33 mmol) and 3-bromo-4-chloroaniline (301 mg, 1.46 mmol) in DMA (3 mL) was stirred at 30 °C for 16 hrs. The reaction was diluted with water and the pH was adjusted to ~8 with sat. Na_2CO_3 . PE was added and the mixture was stirred for 10 minutes. The solid was removed by filtration to afford the title compound as a brown solid (400 mg, 85.5%). MS (ES+) $\text{C}_{13}\text{H}_7\text{BrClFN}_4$ requires: 352, found: 353 $[\text{M}+\text{H}]^+$.

Step 7




[0298] **N⁴-(3-Bromo-4-chlorophenyl)-N⁶-(4-methoxybenzyl)pyrido[3,4-d]pyrimidine-4,6-diamine** A mixture of the product from the previous step (365 mg, 1 mmol) and *p*-methoxybenzylamine (1.37 g, 10 mmol) in DMSO (5 mL) was stirred at 100 °C for 16 h. The reaction was then diluted with H_2O and extracted with EtOAc (20 mL $\times$ 3). The combined organic layer was washed with brine, dried, and concentrated. The crude material was purified by flash column chromatography eluting with PE/EtOAc from 0% to 100% to afford the title compound as a yellow solid (280 mg, 52.5%). MS (ES+) $\text{C}_{21}\text{H}_{17}\text{BrClN}_5\text{O}$ requires: 469, found: 470 $[\text{M}+\text{H}]^+$.

Step 8




[0299] **N⁴-(3-bromo-4-chlorophenyl)pyrido[3,4-d]pyrimidin-2,6-diamine** To a solution of the product from the previous step (280 mg, 0.6 mmol) in DCM (3 mL) was added CF₃COOH (1 mL). The resulting solution was stirred at room temperature for 16 h and then evaporated under vacuum to dryness. The residue was taken up in NH₄OH (2 mL) and stirred for 5 min. The solid was collected by filtration to afford the title compound as a yellow solid (160 mg, 76.9%). MS (ES+) C₁₃H₉BrClN₅ requires: 349, found: 350 [M+H]⁺.

Step 9



[0300] **Diethyl (2-((4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)amino)-2-oxoethyl)phosphonate** A mixture of the product from the previous step (150 mg, 0.43 mmol), 2-(diethoxyphosphoryl)acetic acid (126 mg, 0.64 mmol), T3P (409 mg, 0.64 mmol) and Et₃N (132 mg, 1.31 mmol) in EtOAc (3 mL) was stirred at 30 °C for 16 h. The reaction was diluted with H₂O. The solid that formed was removed by filtration and washed with EtOAc to afford the title compound as a beige solid (200 mg, 88.5%). MS (ES+) C₁₉H₂₀BrClN₅O₄P requires: 527, found: 528 [M+H]⁺.

Step 10




[0301] **(E)-N-(4-((3-Bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide** To a solution of 2,2-dimethoxy-N,N-dimethylethan-1-amine (80 mg, 0.6 mmol) in 0.08 mL of H₂O was added 0.08 mL of 37% HCl. The solution was stirred at 40 °C for 20 hrs and then cooled to 0 °C. This is called solution A. KOH (90 mg, 1.6 mmol) was dissolved in 0.4 mL of H₂O and cooled to 0 °C. This is called solution B. To a solution of the product from the previous step (106 mg, 0.2 mmol) in 0.8 mL of THF and 0.4 mL of DMA was added LiCl (8 mg, 0.2 mmol) at 0 °C under Ar. The mixture was stirred at 0 °C for 15 min. Solution B was added and stirred at 0 °C for 2 min. Solution A was added and stirred for 2 hrs. H₂O (5 mL) and PE (5 mL) were added and the mixture was filtered to afford the title compound as a beige solid (70 mg, 60.9%).

[0302] MS (ES+) C₁₉H₁₈BrClN₆O requires: 460, found: 461 [M+H]⁺.

[0303] ¹H NMR (500 MHz, DMSO) δ 10.98 (s, 1H), 10.39 (s, 1H), 9.03 (d, J = 17.6 Hz, 2H), 8.68 (s, 1H), 8.28 (d, J = 2.3 Hz, 1H), 7.92 (dd, J = 8.8, 2.3 Hz, 1H), 7.67 (d, J = 8.8 Hz, 1H), 6.88 (dt, J = 15.4, 6.0 Hz, 1H), 6.53 (d, J = 15.5 Hz, 1H), 3.11 (d, J = 5.6 Hz, 2H), 2.20 (s, 6H).

Table 1. Example 2

Ex. No	Structure	IUPAC Name	MWt	M+H	Ex. Meth.
--------	-----------	------------	-----	-----	-----------

Ex. No	Structure	IUPAC Name	MWt	M+H	Ex. Meth.
2		(E)-N-(4-((3,4-dichlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide	416	417	3

[0304] The activity of the compounds in Examples 1-2 as HER2 and EGFR inhibitors is illustrated in the following assays. The other compounds listed above, which have not yet been made and/or tested, are predicted to have activity in these assays as well.

Biological Activity Assay

Ba/F3 Cell line generation and IL-3 deprivation

[0305] The Ba/F3 cell line was cultured using incomplete RPMI-1640 medium (R8758; Sigma Life Science) supplemented with L-glutamine, 10% heat-inactivated FBS (Gibco), 1% penicillin–streptomycin (Sigma Life Science), and 10 ng/ml mouse IL-3 (R&D systems) under sterile conditions. Stable cell lines were generated through retroviral transduction of the Ba/F3 cell line for 12 hours. Retroviruses were generated through transfecting pBABE-Puro-based vectors into the Phoenix 293 T Ampho packaging cell line (Orbigen) using Lipofectamine 2000 (Invitrogen). 72 hours after transduction, 2 µg/ml puromycin (Invitrogen) was added to the medium. After 5 days of selection, cells were stained with FITC-conjugated HER2 (Biolegend) or phycoerythrin (PE)-conjugated EGFR (Biolegend) and sorted via FACS. Cell lines were then grown in the absence of IL-3 for 15 days, and cell viability was determined every 3 days using the Cell Titer Glo assay (Promega). Resulting stable cell lines were maintained in the complete RPMI-1640 medium described above without IL-3.

Cell Viability Assay and IC₅₀ Estimation

[0306] Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-well plates (Greiner Bio-One) in technical triplicate. Cells were treated with seven different concentrations of tyrosine kinase inhibitors or vehicle alone at a final volume of 40 µL per well. After 3 days hours, 11 µL of Cell Titer Glo was added to each well. Plates were shaken

for 15 minutes, and bioluminescence was determined using a FLUOstar OPTIMA multi-mode micro-plate reader (BMG LABTECH). Bioluminescence values were normalized to DMSO treated cells, and normalized values were plotted in GraphPad Prism using non-linear regression fit to normalized data with a variable slope. IC₅₀ values were calculated by GraphPad Prism at 50% inhibition.

Inhibition of HER2 mutations

[0307] IC₅₀ estimation is performed for selected Examples against three common HER2 mutations: A775_G776insYVMA(YVMA), P780_Y781insGSP(GSP), and G776delinsVC(VC). Table 2. HER2 Log(IC₅₀, nM)

Selectivity for mutated HER2 over WT EGFR

[0308] A panel of Ba/F3 cell lines is generated expressing HER2 activating mutations, including mutations within the tyrosine kinase domain (spanning exons 19-21) of HER2. Mutations are then evaluated for transforming capability, as demonstrated by cell viability against IL-3 deprivation. IC₅₀ estimation is then performed.

[0309] A selectivity index, defined as the ratio: (HER2 mutant IC₅₀ value / WT EGFR IC₅₀ value) is calculated for each combination of mutant and inhibitor. For a given mutant and inhibitor pairing, therefore, a selectivity ratio less than 1 reflects inhibition of the mutant by inhibitor at a concentration less than inhibition by WT EGFR by the same inhibitor.

Inhibition of mutated EGFR over WT EGFR

Table 2. Selected EGFR Log(IC₅₀, nM)

	1	2
WT	1.05	1.03
A763insFQEA	-0.35	0.16
A767insASV	N.D.	N.D.
D770insG	0.19	0.19
D770insY H773Y	0.66	0.63
N771insSVDNR	0.66	0.98
V769insASV	0.61	0.63
A767insTLA	0.78	0.83
D770del insGY	0.75	0.71

	1	2
H773insAH	0.91	0.88
N771insHH	0.35	0.33
P772insDNP	0.94	0.94
S768I T790M	0.83	0.81
V769insGSV	1.00	0.98
V769insGVV	1.35	1.40
V769insMASVD	0.76	0.88
V769L	0.91	0.98
A763insFQEA	0.51	0.50
A767insASV	0.55	0.51
D770insG	0.57	0.54
D770insY H773Y	0.24	0.22
N771insSVDNR	0.95	1.08
V769insASV	1.01	1.02
H773L / V774M	1.44	1.41
D770insNPG / C797S	2.76	2.73
D770insNPG / T790M	2.25	2.40
S768dupSVD / C797S	3.06	3.06
S768dupSVD / T790M	2.75	2.73

N/D = not determined

Inhibition of mutated HER2 over WT EGFR

[0310] A panel of Ba/F3 cell lines was generated expressing HER2 activating mutations, including mutations within the tyrosine kinase domain (spanning exons 19-21) of HER2. Mutations were then evaluated for transforming capability, as demonstrated by cell viability against IL-3 deprivation. IC₅₀ estimation was then performed for Examples 1 and 2.

Table 3. Selected HER2 Log(IC₅₀, nM)

	1	2
EGFR WT	1.05	1.03
R678Q	0.616	0.692
L755S	3.669	1.300
L755P	5.608	3.299
D769H	0.570	0.734
D769N	0.929	0.369
D769Y	0.585	0.655
V773M	0.497	1.180
V777L	0.499	0.473
Y772dupYVMA	27.553	N/D
G776del insVC	9.295	N/D
G776del insVV	4.826	N/D
G776del insLC	2.129	N/D
G778insLPS	0.873	0.457
P780insGSP	6.278	N/D
L786V	1.642	2.079
V842I	0.822	1.109
L869R	0.773	1.017

N/D = not determined

Selectivity for mutated EGFR over WT EGFR

[0311] A panel of Ba/F3 cell lines is generated expressing EGFR exon 20 mutations. Mutations are then evaluated for transforming capability, as demonstrated by cell viability against IL-3 deprivation. IC₅₀ estimation is then performed.

[0312] A selectivity index, defined as the ratio: (EGFR mutant IC₅₀ value / WT EGFR IC₅₀ value) is then calculated for each combination of mutant and inhibitor. For a given mutant and inhibitor pairing, therefore, a selectivity ratio less than 1 reflects inhibition of the

mutant by inhibitor at a concentration less than inhibition by WT EGFR by the same inhibitor.

In Vivo Activity Assay

In vivo patient derived xenograft (PDX) studies

[0313] HER2 Y772dupYVMA PDX mice were purchased from Jax Labs (Model # TM01446), and EGFR H773insNPH mice were generated as part of the MD Anderson Cancer Center Lung Cancer Moon shot. Fragments from tumors expressing HER2 Y772dupYVMA or EGFR H773insNPH were inoculated into 5- to 6-week old female NSG mice (Jax Labs #005557). Mice were measured three times per week, and when tumors reached a volume of 275-325mm³ mice were randomized into treatment groups: vehicle control (0.5% Methylcellulose, 0.05% Tween-80 in dH₂O), or the indicated dose of the tyrosine kinase inhibitor compound. Tumor volumes and body weight were measured three times per week. Mice received drug orally Monday- Friday (5 days per week). Experiments were completed in agreement with Good Animal Practices and with approval from MD Anderson Cancer Center Institutional Animal Care and Use Committee (Houston, TX).

Tumor inhibition of PDX

[0314] HER2 Y772dupYVMA and EGFR H773insNPH mice are treated with (a) vehicle, (b) 2.5 mg / kg or (c) 5 mg / kg of inhibitor. Percent change of tumor volume and percent change in body weight for the EGFR mice are determined.


[0315] All references, patents or applications, U.S. or foreign, cited in the application are hereby incorporated by reference as if written herein in their entireties. Where any inconsistencies arise, material literally disclosed herein controls.

[0316] From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications of the disclosure to adapt it to various usages and conditions.

CLAIMS

What is claimed is:

1. A compound of structural Formula I



or a salt thereof, wherein:

A^1 is chosen from $\text{C}(\text{R}^1)$ and N;

A^2 is chosen from $\text{C}(\text{R}^2)$ and N;

A^3 is chosen from $\text{C}(\text{R}^3)$ and N;

Ar^1 is chosen from aryl and heteroaryl, either of which is optionally substituted with one or two R^4 groups, and either of which is optionally substituted with one, two, or three R^5 groups;

R^1 is chosen from halo, $-\text{CN}$, $-\text{OR}^6$, $-\text{NR}^{7a}\text{R}^{7b}$, $-\text{COOR}^8$, and $-\text{CONR}^{9a}\text{R}^{9b}$;

R^2 and R^3 are independently chosen from H, alkyl, and alkoxy;

each R^4 is independently chosen from alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which is optionally substituted with one or two R^{10} groups;

each R^5 is independently chosen from halo, $-\text{CN}$, $-\text{OR}^{11}$, $-\text{NR}^{12a}\text{R}^{12b}$, $-\text{COOR}^{13}$, and $-\text{CONR}^{14a}\text{R}^{14b}$;

each R^6 , R^{7a} , and R^{7b} is independently chosen from H, alkyl, and $\text{C}(=\text{O})\text{alkyl}$;

each R^8 , R^{9a} , and R^{9b} is independently chosen from H and alkyl;


each R^{10} is independently chosen from halo, hydroxy, and alkoxy;

each R^{11} , R^{12a} , and R^{12b} is independently chosen from H, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{1-6}\text{haloalkyl}$, and $\text{C}(=\text{O})\text{C}_{1-6}\text{alkyl}$; and


each R^{13} , R^{14a} , and R^{14b} is independently chosen from H and $\text{C}_{1-6}\text{alkyl}$.

2. The compound as recited in claim 1, wherein A^1 is N.
3. The compound as recited in any one of claims 1 – 2, wherein A^2 is N.
4. The compound as recited in any one of claims 1 – 3, wherein A^3 is $\text{C}(\text{H})$.
5. The compound as recited in any one of claims 1 – 4, wherein Ar^1 is chosen from aryl and heteroaryl, either of which is optionally substituted with one, two, or three R^5 groups.

6. The compound as recited in any one of claims 1 – 5, wherein each R⁵ is independently chosen from halo, -CN, and -OR¹¹.
7. The compound as recited in any one of claims 1 – 6, wherein Ar¹ is phenyl which is substituted with one, two, or three R⁵ groups.
8. The compound as recited in claim 7 wherein Ar¹ is chosen from:



9. The compound as recited in claim 1, chosen from:



10. A compound as recited in claim 1 for use as a medicament.
11. A compound as recited in claim 1 for use in the treatment of cancer.
12. A compound as recited in claim 1 for use in the manufacture of a medicament for the prevention or treatment of a disease or condition ameliorated by the inhibition of HER2.
13. A compound as recited in claim 1 for use in the manufacture of a medicament for the prevention or treatment of a disease or condition ameliorated by the inhibition of EGFR.
14. A pharmaceutical composition comprising a compound as recited in claim 1 together with a pharmaceutically acceptable carrier.
15. A method of inhibition of HER2 comprising contacting HER2 with a compound as recited in claim 1.
16. A method of inhibition of EGFR comprising contacting EGFR with a compound as recited in claim 1.
17. A method of treatment of a HER2-mediated disease comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient in need thereof.

18. A method of treatment of an EGFR-mediated disease comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient in need thereof.
19. The method as recited in either one of claims 17 and 18 wherein said disease is cancer.
20. The method as recited in claim 19, wherein the cancer is chosen from small cell lung cancer, non small cell lung cancer, lung adenocarcinoma, colorectal cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, stomach cancer, and uterine cancer.
21. The method as recited in claim 20, wherein the cancer is non small cell lung cancer.
22. A method of treatment of a HER2-mediated disease comprising the administration of:
 - a. a therapeutically effective amount of a compound as recited in claim 1; and
 - b. another therapeutic agent.
23. A method of treatment of an EGFR-mediated disease comprising the administration of:
 - a. a therapeutically effective amount of a compound as recited in claim 1; and
 - b. another therapeutic agent.
24. A method for treatment of an HER2-mediated disease in a subpopulation of subjects, characterized in that the subpopulation of subjects comprises a HER2 mutation, comprising administering a compound as recited in claim 1.
25. The method as recited in claim 24, wherein the HER2-mediated disease is cancer.
26. The method as recited in either one of claims 24 and 25, wherein the HER2 mutation is an exon 20 insertion mutation, excluding C805S.
27. The method as recited in either one of claims 24 and 25, wherein the HER2 mutation is an activating mutation.
28. The method as recited in claim 27, wherein the activating mutation is chosen from an extracellular mutation, an exon 19 point mutation, and an exon 21 point mutation.
29. The method as recited in claim 27, wherein the activating mutation is chosen from L755 and D769.
30. The method as recited in claim 27, wherein the activating mutation is chosen from V842I and L869R.
31. The method as recited in either one of claims 24 and 25, wherein the HER2 mutation is chosen from YVMA, GSP, VC, V754M, L755S, L755P, D769H, D769N, Y772dupYVMA, V773M, G776del insVC, G776delinsVV, G776delinsLC, G778insLPS, G778dupGSP, V777L, G778insLPS, G778dupGSP, L786V, V842I, and L869R.

32. The method as recited in any one of claims 24 – 31, wherein the selectivity of the compound of claim 1 for the HER2 mutation over WT EGFR is 0.5 or less.
33. The method as recited in claim 32, wherein the selectivity of the compound of claim 1 for the HER2 mutation over WT EGFR is 0.1 or less.
34. A method for treatment of an EGFR-mediated disease in a subpopulation of subjects, characterized in that the subpopulation of subjects comprises an EGFR mutation, comprising administering a compound as recited in claim 1.
35. The method as recited in claim 34, wherein the EGFR-mediated disease is cancer.
36. The method as recited in either one of claims 34 and 35, wherein the EGFR mutation is an exon 20 insertion mutation excluding C797S.
37. The method as recited in either one of claims 34 and 35, wherein the HER2 mutation is an atypical mutation.
38. The method as recited in claim 37, wherein the atypical mutation is chosen from L719, G724, and L792.
39. The method as recited in either one of claims 34 and 35, wherein the EGFR mutation is chosen from S768I, S768dupSVD, D770insNPG, D770insSVD, V774insHV, A763insFQEA, A767insASV, S768I T790M, V769L, A767insTLA, V769insMASVD, V769insGSV, V769insGVV, V769insASV, D770del insGY, D770insY H773Y, D770insG, N771insSVDNR, N771insHH, P772insDNP, A763insFQEA, A767insASV, A767insTLA, S768I, S768dupSVD, V769L, V769insASV, V769insGSV, V769insGVV, V769insMASVD, D770del insGY, D770insY H773Y, D770insNPG, D770insG, D770insSVD, N771insSVDNR, N771insHH, P772insDNP, H773insAH, H773insNPH, H773insH, H773L V774M, V774insHVVH773insAH H773L / V774M, D770insNPG / C797S, D770insNPG / T790M, S768dupSVD / C797S, S768dupSVD / T790M, and H773insNPH.
40. The method as recited in any one of claims 34 – 39, wherein the selectivity of the compound of claim 1 for the EGFR mutation over WT EGFR is 0.5 or less.
41. The method as recited in claim 40, wherein the selectivity of the compound of claim 1 for the EGFR mutation over WT EGFR is 0.1 or less.
42. A method for treating a cancer or tumor in a subject in need of treatment comprising the steps of:
- (a) determining the HER2 genotype of the subject,
 - (b) identifying the presence of an HER2 mutation in the genotype of the subject; and

- (c) administering a compound of claim 1, or a salt thereof, wherein the compound of claim 1 is selective for the HER2 mutation over WT EGFR.
43. The method as recited in claim 42, wherein the selectivity of the compound of claim 1 for the HER2 mutation over WT EGFR is 0.5 or less.
44. The method as recited in claim 43, wherein the selectivity of the compound of claim 1 for the HER2 mutation over WT EGFR is 0.1 or less.
45. The method as recited in any one of claims 42 – 44, wherein the HER2 mutation is chosen from YVMA, GSP, VC, V754M, L755S, L755P, D769H, D769N, Y772dupYVMA, V773M, G776del insVC, G776delinsVV, G776delinsLC, G778insLPS, G778dupGSP, V777L, G778insLPS, G778dupGSP, L786V, V842I, and L869R.
46. A method for treating a cancer or tumor in a subject in need of treatment comprising the steps of:
- (d) determining the EGFR genotype of the subject,
 - (e) identifying the presence of an EGFR mutation in the genotype of the subject; and
 - (f) administering a compound of claim 1, or a salt thereof, wherein the compound of claim 1 is selective for the EGFR mutation over WT EGFR.
47. The method as recited in claim 46, wherein the selectivity of the compound of claim 1 for the EGFR mutation over WT EGFR is 0.5 or less.
48. The method as recited in claim 47, wherein the selectivity of the compound of claim 1 for the EGFR mutation over WT EGFR is 0.1 or less.
49. The method as recited in claim 48, wherein the EGFR mutation is chosen from S768I, S768dupSVD, D770insNPG, D770insSVD, V774insHV, A763insFQEA, A767insASV, S768I T790M, V769L, A767insTLA, V769insMASVD, V769insGSV, V769insGVV, V769insASV, D770del insGY, D770insY H773Y, D770insG, N771insSVDNR, N771insHH, P772insDNP, A763insFQEA, A767insASV, A767insTLA, S768I, S768dupSVD, V769L, V769insASV, V769insGSV, V769insGVV, V769insMASVD, D770del insGY, D770insY H773Y, D770insNPG, D770insG, D770insSVD, N771insSVDNR, N771insHH, P772insDNP, H773insAH, H773insNPH, H773insH, H773L V774M, V774insHVH773insAH H773L / V774M, D770insNPG / C797S, D770insNPG / T790M, S768dupSVD / C797S, S768dupSVD / T790M, and H773insNPH.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2020/029851**A. CLASSIFICATION OF SUBJECT MATTER****C07D 471/04(2006.01)i, A61K 31/519(2006.01)i, A61K 45/06(2006.01)i, A61P 35/00(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D 471/04; A61K 31/519; C07D 239/94; C07D 403/02; C07D 403/12; C07D 495/04; C07K 14/71; A61K 45/06; A61P 35/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal), STN(Registry, Caplus) & keywords: tyrosine kinase inhibitor, cancer, EGFR, HER2

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2019-051155 A1 (THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE) 14 March 2019 claim 1; figure 1; page 2, lines 14-17, page 53, line 28-page 54, line 13, page 94, lines 22-25, page 98, lines 20- page 99, line 16, page 101, lines 9-22	1-3,9-16
X	WO 2011-028135 A1 (AUCKLAND UNISERVICES LIMITED) 10 March 2011 claims 1, 35, 37; page 4, page 74, line 1-page 75, line 8	1-3,9-16
A	SMAILL, J. B. et al., "Tyrosine Kinase Inhibitors. 20. Optimization of substituted quinazoline and pyrido[3,4-d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family", Journal of Medicinal Chemistry, 2016, Vol. 59, No. 17, pages 8103-8124 the whole document	1-3,9-16
A	WO 97-38983 A1 (WARNER-LAMBERT COMPANY) 23 October 1997 the whole document	1-3,9-16
A	WO 2007-005455 A2 (FMC CORPORATION et al.) 11 January 2007 the whole document	1-3,9-16



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

03 August 2020 (03.08.2020)

Date of mailing of the international search report

03 August 2020 (03.08.2020)

Name and mailing address of the ISA/KR

International Application Division

Korean Intellectual Property Office

189 Cheongsa-ro, Seo-gu, Daejeon, 35208, Republic of Korea



Facsimile No. +82-42-481-8578

Authorized officer

Jung, Da Won

Telephone No. +82-42-481-5373



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2020/029851

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 17-49
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 17-49 pertain to methods for treatment of the human body by surgery or therapy, as well as diagnostic methods(PCT Article 17(2)(a)(i) and Rule 39.1(iv)).
2. ☒ Claims Nos.: 8,33,41
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims 8, 33, 41 are regarded to be unclear because they refer to claims which do not comply with PCT Rule 6.4(a).
3. ☒ Claims Nos.: 4-7,32,40
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2020/029851

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2019-051155 A1	14/03/2019	AU 2018-330171 A1 CA 3074017 A1 KR 10-2020-0072478 A SG 11202002060 A	12/03/2020 14/03/2019 22/06/2020 29/04/2020
WO 2011-028135 A1	10/03/2011	AU 2010-221818 A1 AU 2010-290199 A1 AU 2010-290199 B2 CA 2754808 A1 CA 2754808 C CA 2771016 A1 CN 102348708 A CN 102574846 A CN 102574846 B CN 104496982 A CN 105541836 A EP 2406262 A1 EP 2406262 B1 EP 2473509 A1 EP 3031807 A1 JP 2012-520295 A JP 2013-503859 A JP 2016-094432 A JP 5793428 B2 JP 5925680 B2 KR 10-2011-0130468 A KR 10-2012-0076350 A MX 2011009034 A MX 2012002327 A MX 336332 B NZ 595206 A NZ 598144 A NZ 620000 A RU 2011141121 A RU 2012112396 A RU 2568639 C2 US 2012-0077811 A1 US 2012-0202832 A1 US 2016-0002222 A1 US 2016-0031877 A1 US 9073916 B2 US 9101632 B2 WO 2010-104406 A1 WO 2010-104406 A8 ZA 201105917 B ZA 201200994 B	06/10/2011 01/03/2012 27/10/2016 16/09/2010 08/01/2019 10/03/2011 08/02/2012 11/07/2012 03/12/2014 08/04/2015 04/05/2016 18/01/2012 17/02/2016 11/07/2012 15/06/2016 06/09/2012 04/02/2013 26/05/2016 14/10/2015 25/05/2016 05/12/2011 09/07/2012 22/09/2011 10/04/2012 15/01/2016 28/02/2014 31/01/2014 31/07/2015 20/04/2013 10/10/2013 20/11/2015 29/03/2012 09/08/2012 07/01/2016 04/02/2016 07/07/2015 11/08/2015 16/09/2010 16/09/2010 27/06/2012 31/10/2012
WO 97-38983 A1	23/10/1997	AU 2446397 A AU 725533 B2	07/11/1997 12/10/2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2020/029851

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		BG 102811 A	30/11/1999
		BG 63160 B1	31/05/2001
		BR 9708640 A	03/08/1999
		BR 9708640 B1	11/06/2013
		CA 2249446 A1	23/10/1997
		CA 2249446 C	17/06/2008
		CN 100503580 C	24/06/2009
		CN 1145614 C	14/04/2004
		CN 1218456 A	02/06/1999
		CN 1495172 A	12/05/2004
		CN 1923818 A	07/03/2007
		DE 69710712 T2	07/11/2002
		DE 69710712 T3	23/12/2010
		DK 0892789 T3	03/06/2002
		DK 0892789 T4	06/04/2010
		EA 001595 B1	25/06/2001
		EA 199800887 A1	24/06/1999
		EE 05289 B1	15/04/2010
		EE 9800328 A	15/04/1999
		EP 0892789 A1	27/01/1999
		EP 0892789 B1	27/02/2002
		EP 0892789 B2	18/11/2009
		ES 2174250 T3	01/11/2002
		ES 2174250 T5	21/04/2010
		GE P20012442 B	10/02/2001
		HK 1019739 A1	18/02/2005
		HK 1064675 A1	24/12/2009
		HU 228446 B1	28/03/2013
		HU 9901207 A2	28/07/1999
		HU 9901207 A3	28/11/2001
		JP 2000-508657 A	11/07/2000
		JP 3370340 B2	27/01/2003
		KR 10-0545274 B1	12/04/2006
		KR 10-2000-0005364 A	25/01/2000
		NZ 332119 A	31/08/2001
		SI 0892789 T1	30/06/2002
		SI 0892789 T2	31/03/2010
		SK 141798 A3	16/05/2000
		SK 284073 B6	08/09/2004
		US 2003-0229051 A1	11/12/2003
		US 6344459 B1	05/02/2002
		US 6602863 B1	05/08/2003
		US 7786131 B2	31/08/2010
		ZA 9703060 B	04/11/1997
WO 2007-005455 A2	11/01/2007	WO 2007-005455 A3	14/06/2007